

EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

1

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

THERAPEUTIC DRUG CLASS	PREFERRED AGENTS	NON-PREFERRED AGENTS	PA CRITERIA
ACNE AGENTS			
	ANTI-IN	IFECTIVE	
	clindamycin gel (generic Cleocin-T) clindamycin lotion clindamycin solution	ACZONE (dapsone) AKNE-MYCIN (erythromycin) azelaic acid AMZEEQ FOAM (minocycline) AZELEX (azelaic acid) CLEOCIN-T (clindamycin) CLINDAMYCIN PAC (clindamycin) CLINDAGEL (clindamycin) CLINDAGEL (clindamycin) clindamycin foam clindamycin gel daily (generic Clindagel) dapsone ERY (erythromycin) ERYGEL (erythromycin) erythromycin gel, swabs, solution EVOCLIN (clindamycin) KLARON (sulfacetamide) sulfacetamide	 Maximum Age Limit 21 years – all agents except isotretinoins
	RET	INOIDS	
	RETIN-A (tretinoin) tretinoin cream	adapalene AKLIEF (trifarotene) ALTRENO (tretinoin) ARAZLO (tazarotene) ATRALIN (tretinoin) AVITA (tretinoin) DIFFERIN (adapalene) FABIOR (tazarotene) PLIXDA (adapalene)	

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

-have electronic if A functionality. However, may must adhere to Wedleard 31 A e		
	RETIN-A MICRO (tretinoin)	
	tazarotene	
	TAZORAC (tazarotene)	
	tretinoin gel	
	tretinoin micro	
COMBINATION	DRUGS/OTHERS	
adapalene/benzoyl peroxide	ACANYA (benzoyl peroxide/clindamycin)	
benzoyl peroxide/clindamycin (generic DUAC)	AKTIPAK (erythromycin/benzoyl peroxide)	
sodium sulfacetamide/sulfur foam/gel/suspension	BENZACLIN GEL (benzoyl peroxide/clindamycin)	
SSS 10/5 Cream (sodium sulfacetamide/sulfur)	BENZACLIN KIT (benzoyl peroxide/ clindamycin)	
	BENZAMYCIN PAK (benzoyl peroxide/	
	erythromycin)	
	DUAC (benzoyl peroxide/clindamycin)	
	EPIDUO (adapalene/benzoyl peroxide)	
	EPIDUO FORTE (adapalene/benzoyl peroxide)	
	erythromycin/benzoyl peroxide	
	INOVA 4/1 (benzoyl peroxide/salicylic acid)	
	INOVA 8/2 (benzoyl peroxide/salicylic acid)	
	NEUAC (benzoyl peroxide/clindamycin)	
	ONEXTON (benzoyl peroxide/clindamycin) PRASCION (sulfacetamide sodium/sulfur)	
	ROSANIL (sulfacetamide sodium/sulfur)	
	SE BPO (benzoyl peroxide)	
	sodium sulfacetamide/sulfur	
	cleanser/cream/lotion/pads	
	sodium sulfacetamide/sulfur/meratan	
	SSS 10/5 Foam (sodium sulfacetamide/sulfur)	
	sulfacetamide sodium/sulfur/urea	
	VELTIN (clindamycin/tretinoin)	
	ZENCIA WASH (sulfacetamide sodium/sulfur)	
	ZIANA (clindamycin/tretinoin)	
KERATOLYTICS (B	ENZOYL PEROXIDES)	

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F

2



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

benzoyl peroxide bar, cleanser, cream, gel, lotion, wash ^{Rx & OTC}	benzoyl peroxide foam ^{Rx & OTC} BP 5.5% (benzoyl peroxide) BPO (benzoyl peroxide) ^{Rx & OTC} INOVA (benzoyl peroxide) LAVOCLEN (benzoyl peroxide) PANOXYL BAR 10% (benzoyl peroxide) ^{OTC} PANOXYL CREAM 3% (benzoyl peroxide) ^{OTC} OC8 GEL (benzoyl peroxide) ^{OTC}	
ISOTI	RETINOIN	
AMNESTEEM (isotretinoin)	ABSORICA (isotretinoin)	Available for all ages
CLARAVIS (isotretinoin) isotretinoin MYORISAN(isotretinoin) ZENATANE (isotretinoin)	ABSORICA LD(isotretinoin)	
ALPHA-1 PROTEINASE INHIBITORS		
ARALAST (alpha-1 proteinase inhibitor) GLASSIA (alpha-1 proteinase inhibitor) PROLASTIN C (alpha-1 proteinase inhibitor) ZEMAIRA (alpha-1 proteinase inhibitor)		
ALZHEIMER'S AGENTS SmartPA		
CHOLINESTER	ASE INHIBITORS	
donepezil (tablets and ODT) 5mg, 10mg galantamine galantamine ER rivastigmine capsules rivastigmine patches	ARICEPT (donepezil) ARICEPT 23 MG (donepezil) ARICEPT ODT (donepezil) donepezil 23mg EXELON Capsules (rivastigmine)	 All Agents Documented diagnosis for both preferred and non-preferred Non-Preferred Criteria

3

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	EXELON Patches (rivastigmine) EXELON Solution (rivastigmine) RAZADYNE (galantamine) RAZADYNE ER (galantamine)	Have tried 2 different preferred agents in the past 6 months
	NMDA RECEPTOR ANTAGONIST	
memantine	NAMENDA TABS (memantine) NAMENDA SOLUTION(memantine) NAMENDA XR (memantine) memantine XR	
	COMBINATION AGENTS	
	NAMZARIC (memantine/donepezil)	 Namzaric Documented diagnosis AND 30 days of concurrent therapy with donepezil + memantine in the past 6 months
ANALGESICS, NARCOTIC - SHORT ACTING		
acetaminophen/codeine benzhydrocodone/APAP codeine dihydrocodeine/ APAP/caffeir ENDOCET (oxycodone/APAP hydrocodone/APAP hydromorphone morphine oxycodone capsules oxycodone liquid oxycodone tablets oxycodone tablets oxycodone/APAP oxycodone/APAP oxycodone/APAP	ABSTRAL (fentanyl) ACTIQ (fentanyl) APADAZ (benzhydrocodone/APAP) butalbital/APAP/caffeine/codeine	 MS DOM Opioid Initiative Short-Acting Opioids Long-Acting Opioids Morphine Equivalent Daily Dose Concomitant use of Opioids and Benzodiazepines Criteria details found here Minimum Age Limit 18 years – tramadol and codeine products Quantity Limit Applicable <u>quantity limit</u> in 31 rolling days. 62 tablets – bultalbital/codeine combinations, codeine,

4

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

tramadol tramadol/APAP	hydrocodone/ibuprofen IBUDONE (hydrocodone/ibuprofen) LAZANDA NASAL SPRAY (fentanyl) levorphanol LORCET (hydrocodone/APAP) LORTAB (hydrocodone/APAP) MAGNACET (oxycodone/APAP) meperidine solution meperidine solution meperidine solution MAGNACET (oxycodone/APAP) NORCO (hydrocodone/APAP) NUCYNTA (tapentadol) ONSOLIS (fentanyl) OPANA (oxymorphone) OXAYDO (oxycodone) oxymorphone pentazocine/naloxone PERCOCET (oxycodone/APAP) PERCODAN (oxycodone/APAP) PERCODAN (oxycodone/APAP) PROLATE (oxycodone/APAP) REPREXAINE (hydrocodone/ibuprofen) ROXICET (oxycodone/APAP) REPREXAINE (hydrocodone/ibuprofen) ROXICET (oxycodone) ROXYBOND (oxycodone) ROXYBOND (oxycodone) RYBIX (tramadol) SUBSYS (fentanyl) SYNALGOS-DC (dihydrocodeine/ aspirin/caffeine) TYLENOL W/CODEINE (APAP/APAP) ULTRACET (tramadol/APAP) ULTRACET (tramadol) VICODIN (hydrocodone/APAP)	dihydrocodeine combinations, fentanyl, hydromorphone, levorphanol, meperidine, morphine, oxycodone, oxycodone/ibuprofen, oxymorphone, pentazocine, tapentadol, tramadol • 62 tablets CUMULATIVE – hydrocodone combinations, oxycodone combinations • 124 tablets – butalbital/APAP 750 • 145 tablets – butalbital/APAP 650 • 186 tablets – butalbital/APAP 325, butalbital/ASA 325 • 5mL (2 x 2.5 bottles) – butorphanol nasal • 180 mL CUMULATIVE – oxycodone liquids
---------------------------	---	--

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F

5



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

	y. However, they must adhere to Medicaid's PA cr	riteria. VICOPROFEN (hydrocodone/ibuprofen) XODOL (hydrocodone/acetaminophen) ZAMICET (hydrocodone/APAP) ZOLVIT (hydrocodone/APAP) ZYDONE (hydrocodone/acetaminophen)	
ANALGESICS, NARCOT	IC - LONG ACTING SmartPA		
f	BUTRANS (buprenorphine) fentanyl patches morphine ER tablets	ARYMO ER (morphine) BELBUCA (buprenorphine) buprenorphine patch CONZIP ER (tramadol) DOLOPHINE (methadone) DURAGESIC (fentanyl) EMBEDA (morphine/naltrexone) EXALGO (hydromorphone) hydromorphone ER HYSINGLA ER (hydrocodone) KADIAN (morphine) methadone MORPHABOND (morphine) morphine ER capsules MS CONTIN (morphine) NUCYNTA ER (tapentadol) OPANA ER (oxymorphone) oxycodone ER OXYCONTIN (oxycodone) oxymorphone ER RYZOLT (tramadol) tramadol ER	 MS DOM Opioid Initiative Short-Acting Opioids Long-Acting Opioids Morphine Equivalent Daily Dose Concomitant use of Opioids and Benzodiazepines Criteria details found here Minimum Age Limit 18 years – Xartemis XR, Zohydro ER, tramadol products Quantity Limit Applicable guantity limit per rolling days 31 tablets/31 days - Conzip ER, Exalgo ER, Hysingla ER, Ryzolt, Ultram ER 62 tablets/31 days – Arymo ER, Belbuca, Embeda, Kadian, methadone, Morphabond, morphine ER, Nucynta ER, Opana ER,

6

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

	Application (SmartPA) is a proprietary electronic pri lity. However, they must adhere to Medicaid's PA c	or authorization system used for Medicaid fee for serv criteria. ULTRAM ER (tramadol) XARTEMIS XR (oxycodone/APAP) XTAMPZA (oxycodone myristate) ZOHYDRO ER (hydrocodone bitartrate)	vice claims. MSCAN plans may/may not oxycodone ER, Oxycontin, Xtampza ER, Zohydro ER • 10 patches/31 days – Duragesic • 4 patches/31 days – Butrans • 40 tablets/10 days – Xartemis XR Non-Preferred Criteria • Have tried 2 different preferred agents in the past 6 months OR • Documented diagnosis of cancer OR Antineoplastic therapy AND • 90 consecutive days on the requested agent in the past 105 days
ANALGESICS/ANESTH	HETICS (Topical) diclofenac sodium 1% gel diclofenac sodium solution VOLTAREN Gel (diclofenac sodium) ^{SmartPA}	capsaicin DICLO GEL KIT(diclofenac sodium) FLECTOR (diclofenac epolamine) SmartPA FROTEK (ketoprofen) LIDAMANTLE HC (lidocaine/hydrocortisone) LIDO TRANS PAK (lidocaine) lidocaine lidocaine 5% patch lidocaine/prilocaine LIDODERM (lidocaine) SmartPA LIDTOPIC MAX (lidocaine) PENNSAID Solution (diclofenac sodium) SmartPA SYNERA (lidocaine/tetracaine) TRANZAREL (lidocaine) XRYLIDERM (lidocaine)	 Non-Preferred Criteria Have tried 1 preferred agent in the past 6 months Lidoderm Documented diagnosis of Herpetic Neuralgia OR Documented diagnosis of Diabetic Neuropathy ZTlido Documented diagnosis of Herpetic Neuralgia

7

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		xylocaine ZOSTRIX (capsaicin) ZTlido (lidocaine)	
ANDROGENIC AGEN	TS SmartPA		
	ANDRODERM (testosterone patch) testosterone gel packets	ANDROGEL (testosterone gel) ANDROXY (fluoxymesterone) AXIRON (testosterone gel) FORTESTSA (testosterone gel) JATENZO (testosterone undecanoate) NATESTO (testosterone) STRIANT (testosterone) TESTIM (testosterone gel) testosterone pump VOGELXO (testosterone) XYOSTED (testosterone enanthate)	 All Agents Limited to male gender Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months
ANGIOTENSIN MODU			
	Ad benazepril captopril enalapril fosinopril lisinopril quinapril ramipril trandolapril	CE INHIBITORS ACCUPRIL (quinapril) ACEON (perindopril) ALTACE (ramipril) EPANED (enalapril) LOTENSIN (benazepril) MAVIK (trandolapril) moexipril perindopril PRINIVIL (lisinopril) QBRELIS (lisinopril) UNIVASC (moexipril) VASOTEC (enalapril) ZESTRIL (lisinopril)	 Minimum Age Limit ≤ 6 years – Epaned <u>Smart PA will</u> automatically be issued for this age Non-Preferred Criteria Have tried 2 different preferred single entity agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days

8

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	ACE INHIBITOR COMBINATIONS	
benazepril/amlodipine benazepril/HCTZ captopril/HCTZ enalapril/HCTZ fosinopril/HCTZ lisinopril/HCTZ quinapril/HCTZ trandolapril/verapamil	ACCURETIC (quinapril/HCTZ) CAPOZIDE (captopril/HCTZ) LOTENSIN HCT (benazepril/HCTZ) LOTREL(benazepril/amlodipine) moexipril/HCTZ PRESTALIA (perindopril/amlodipine) PRINZIDE (lisinopril/HCTZ) TARKA (trandolapril/verapamil) UNIRETIC (moexipril/HCTZ) VASERETIC (enalapril/HCTZ) ZESTORETIC (lisinopril/HCTZ)	 Non-Preferred Criteria ACE Inhibitor/CCB Have tried 2 different preferred <u>ACEI/CCB</u> agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days ACE Inhibitor/Diuretic Have tried 2 different preferred <u>ACEI/Diuretic</u> agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
A	IGIOTENSIN II RECEPTOR BLOCKERS (ARBs)	
irbesartan losartan olmesartan telmisartan valsartan	ATACAND (candesartan) AVAPRO (irbesartan) BENICAR (olmesartan) candesartan COZAAR (losartan) DIOVAN (valsartan) EDARBI (azilsartan) eprosartan MICARDIS (telmisartan) TEVETEN (eprosartan)	 Non-Preferred Criteria Have tried 2 different preferred <u>single entity</u> agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
ENTRESTO (valsartan/sact		Entresto
irbesartan/HCTZ	AVALIDE (irbesartan/HCTZ)	 Age ≥ 18 years AND

9

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

losartan/F olmesarta olmesarta telmisarta valsartan/	n/amlodipine n/HCTZ n/HCTZ ⁄amlodipine ⁄amlodipine/HCTZ	AZOR (olmesartan/amlodipine) BENICAR-HCT (olmesartan/HCTZ) BYVALSON (nebivolol/valsartan) candesartan/HCTZ DIOVAN-HCT (valsartan/HCTZ) EDARBYCLOR (azilsartan/chlorthalidone) EXFORGE (valsartan/amlodipine) EXFORGE HCT (valsartan/amlodipine/HCTZ) HYZAAR (losartan/HCTZ) MICARDIS-HCT (telmisartan/HCTZ) olmesartan/amlodipine/HCTZ telmisartan/amlodipine TEVETEN-HCT (eprosartan/HCTZ) TRIBENZOR (olmesartan/amlodipine/HCTZ) TWYNSTA (telmisartan/amlodipine)	 Documented diagnosis of heart failure OR Age ≥ 1 year AND Documented diagnosis of heart failure with systemic ventricular systolic dysfunction Non-Preferred Criteria ARB/Beta Blocker, ARB/CCB or ARB/CCB/Diuretic Have tried 1 preferred <u>ARB/CCB</u> agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days ARB/Diuretic Have tried 2 different preferred <u>ARB/Diuretic</u> products in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
		N INHIBITORS	
	DIRECT REN	TEKTURNA (aliskiren)	Non-Preferred Criteria
			 Documented diagnosis of hypertension AND

10

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		KETEK (telithromycin)	
ANTIBIOTICS (MISCEL		DLIDES	
ANTIBIOTICS (GI)	FIRVANQ (vancomycin) metronidazole neomycin tinidazole	DIFICID (fidaxomicin) FLAGYL (metronidazole) FLAGYL ER (metronidazole) paromomycin TINDAMAX (tinidazole) VANCOCIN (vancomycin) vancomycin XIFAXAN (rifaximin)	
	DIRECT RENIN INHIB	ITOR COMBINATIONS AMTURNIDE (aliskiren/amlodipine/hctz) TEKAMLO (aliskiren/amlodipine) TEKTURNA-HCT (aliskiren/hctz) VALTURNA (aliskiren/valsartan)	 days Non-Preferred Criteria Documented diagnosis of hypertension AND Have tried 2 different preferred <u>ACEI or ARB diuretic agents</u> in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
			 Have tried 2 different preferred <u>ACEI or ARB single-entity</u> products in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F

11



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

LINCOS	AMIDE ANTIBIOTICS	
clindamycin capsules clindamycin solution	CLEOCIN (clindamycin) CLEOCIN SOLUTION (clindamycin)	
M	IACROLIDES	
azithromycin clarithromycin ER clarithromycin IR clarithromycin suspension E.E.S. Suspension 200 (erythromycin ethylsuccinate) ERY-TAB (erythromycin) erythromycin	 BIAXIN (clarithromycin) BIAXIN SUSPENSION (clarithromycin) BIAXIN XL (clarithromycin) E.E.S. (erythromycin ethylsuccinate) E.E.S. Suspension 400 (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED Suspension (erythromycin ethylsuccinate) ERYTHROCIN (erythromycin stearate) erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) 	
NITROFU	JRAN DERIVATIVES	
nitrofurantoin nitrofurantoin monohydrate macrocyrstals	FURADANTIN (nitrofurantoin) MACROBID (nitrofurantoin monohydrate macrocyrstals) MACRODANTIN (nitrofurantoin)	
OXA	AZOLIDINONES	
	SIVEXTRO (tedizolid) ZYVOX (linezolid)	Sivextro – <u>MANUAL PA</u> Zyvox - <u>MANUAL PA</u> Quantity Limit • 6 tablets/month – Sivextro

12

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	PLEURO	MUTLINS	
		XENLETA (lefamulin)	
ANTIBIOTICS (Topical)			
	bacitracin ^{oTC} bacitracin/polymixin ^{OTC} gentamicin sulfate mupirocin ointment neomycin/bacitracin/polymyxin ^{OTC}	ALTABAX (retapamulin) CORTISPORIN (bacitracin/neomycin/ polymyxin/HC) mupirocin cream NEOSPORIN (neomycin/bacitracin/polymyxin) ^{OTC} XEPI (ozenoxacin)	
ANTIBIOTICS (VAGINA	AL)		
	CLEOCIN OVULES (clindamycin) CLINDESSE (clindamycin) metronidazole vaginal	AVC (sulfanilamide) CLEOCIN CREAM (clindamycin) clindamycin cream METROGEL (metronidazole) NUVESSA (metronidazole) SOLOSEC (secnidazole) VANDAZOLE (metronidazole)	
ANTICOAGULANTS Sm	artPA		
	O	RAL	
	COUMADIN (warfarin) ELIQUIS (apixaban) PRADAXA (dabigatran) warfarin XARELTO (rivaroxaban)	BEVYXXA (betrixaban) SAVAYSA (edoxaban tosylate)	 <u>DVT Prophylaxis - following hip</u> <u>replacement</u> XARELTO 10MG, ELIQUIS, PRADAXA 110MG 70 total days of therapy per calendar year Documented diagnosis of hip replacement AND Duration of therapy limited to 35 days

13

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.


A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.



14

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

enoxaparin	ARIXTRA (fondaparinux)	LMWH – All Agents
	fondaparinux FRAGMIN (dalteparin) LOVENOX (enoxaparin) Prefilled Syringe	 LMWH therapy in the past 3 months AND Documented diagnosis of cancer OR Female and age 8 to 51 years OR NO LMWH therapy in the past 3 months AND Duration of therapy is ≤ 17 days OR Documented diagnosis of cancer OR Female age 8 to 51 years OR Total hip/knee replacement or hip fracture surgery in the past 6 months AND Duration of therapy ≤ 35 days LMWH Non-Preferred Criteria Have tried 1 different preferred agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
ANTICONVULSANTS SmartPA		
	ADJUVANTS	
carbamazepine carbamazepine suspension carbamazepine ER DEPAKOTE ER (divalproex) DEPAKOTE SPRINKLE (divalproex) divalproex	APTIOM (eslicarbazepine) BANZEL (rufinamide) BRIVIACT (brivaracetam) carbamazepine XR CARBATROL (carbamazepine) DEPAKENE (valproic acid)	Minimum Age Limit • 1 year – Banzel, Epidiolex • 2 years – Diacomit, Onfi, Sympazan Non-Preferred Criteria

15

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

divalproex sprinkle EPITOL (carbamazepine) gabapentin GABITRIL (tiagabine) lamotrigine levetiracetam levetiracetam ER oxcarbazepine oxcarbazepine suspension topiramate tablet topiramate sprinkle capsule valproic acid VIMPAT (lacosamide) zonisamide	DIACOMIT (stiripentol) EPIDIOLEX (cannabidiol) EQUETRO (carbamazepine) felbamate FELBATOL (felbamate) FYCOMPA (perampanel) KEPPRA (levetiracetam) KEPPRA XR (levetiracetam) LAMICTAL (lamotrigine) LAMICTAL CHEWABLE (lamotrigine) LAMICTAL ODT (lamotrigine) LAMICTAL ODT (lamotrigine) lamotrigine ER/XR lamotrigine ODT NEURONTIN (gabapentin) OXTELLAR XR (oxcarbazepine) QUDEXY XR (topiramate) ROWEEPRA (levetiracetam) SABRIL (vigabatrin) SPRITAM (levetiracetam) SABRIL (vigabatrin) SPRITAM (levetiracetam) STAVZOR (valproic acid) TEGRETOL (carbamazepine) TEGRETOL XR (carbamazepine) TEGRETOL XR (carbamazepine) TEGRETOL XR (carbamazepine) TOPAMAX TABLET (topiramate) TOPAMAX Sprinkle (topiramate) topiramate ER (generic Qudexy XR) ^{Step Edit} TRILEPTAL Tablets (oxcarbazepine) TRILEPTAL Suspension (oxcarbazepine)	agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days days AND Documented diagnosis of seizure Banzel/Onfi/Sympazan Documented diagnosis of Lennox- Gastaut AND Have tried 1 different preferred agent for Lennox-Gastaut in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days days AND Documented diagnosis of seizure Diacomit Documented diagnosis of Dravet syndrome AND Active claim for clobazam Epidiolex Documented diagnosis of Dravet syndrome or seizures associated with tuberous sclerosis complex OR Documented diagnosis of Lennox- Gastaut AND Have tried 1 different preferred agent for Lennox-Gastaut in the past 6 months OR 1 claim for the requested agent in the past 30 days
--	---	---

16

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	vigabatrin XCOPRI (cenobamate)	 Fintepla Requires clinical review Sabril Powder for Oral Solution Documented diagnosis of infantile spasms OR Have tried 2 different preferred agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days days AND Documented diagnosis of seizure Topiramate ER – Step Edit 90 consecutive days on the requested agent in the past 105 days AND Documented diagnosis of seizure
		 OR 30 day trial with topiramate IR in the past 6 months
SELECTED BEI	NZODIAZEPINES	
clobazam diazepam rectal gel NAYZILAM (midazolam) VALTOCO (diazepam)	DIASTAT (diazepam rectal) DIASTAT ACCUDIAL (diazepam rectal) ONFI (clobazam) ONFI SUSPENSION (clobazam) SYMPAZAN (clobazam)	 Minimum Age Limit 12 years – Nayzilam 6 years – Valtoco Quantity Limit 2 Twin Packs/31 days – Diastat 2 Packages /31 days – Nayzilam 2 Cartons/31 days - Valtoco

17

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	HYDAI	NTOINS	
DILANTIN (phe PHENYTEK (p phenytoin	•	PEGANONE (ethotoin)	
	SUCCII	NIMIDES	
ethosuximide		CELONTIN (methsuximide) ZARONTIN (ethosuximide)	
ANTIDEPRESSANTS, OTHER Smarth	PA		
bupropion bupropion SR bupropion XL TRINTELLIX (v mirtazapine trazodone venlafaxine venlafaxine ER VIIBRYD (vilaz	vortioxetine) capsules	APLENZIN (bupropion HBr) desvenlafaxine ER desvenlafaxine fumarate ER DESYREL (trazodone) DRIZALMA SPRINKLE (duloxetine) EFFEXOR (venlafaxine) EFFEXOR XR (venlafaxine) EMSAM (selegiline transdermal) FETZIMA ER (levomilnacipran) FORFIVO XL (bupropion) KHEDEZLA ER (desvenlafaxine) MARPLAN (isocarboxazid) NARDIL (phenelzine)	 Minimum Age Limit 18 years - all drugs 7-17 years - duloxetine (except Drizalma Sprinkle) Smart PA will automatically be issued for this age range with a diagnosis of GAD (generalized anxiety disorder) 7-11 years - Drizalma Sprinkle Smart PA will automatically be issued for this age range with a diagnosis of GAD (generalized anxiety disorder)
		nefazodone OLEPTRO ER (trazodone) PARNATE (tranylcypromine) phenelzine PRISTIQ (desvenlafaxine) REMERON (mirtazapine)	 Non-Preferred Criteria Have tried 2 different preferred ^{(Antidepressants, Other' Class} in the past 6 months OR Have tried BOTH a preferred ^{(Antidepressant, SSRI' and}

18

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		tranylcypromine venlafaxine XR venlafaxine ER tablets WELLBUTRIN (bupropion) WELLBUTRIN SR (bupropion) WELLBUTRIN XL (bupropion HCI)	 <u>'Antidepressants, Other'</u> in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days Cymbalta and Irenka (see Fibromyalgia Agents)
ANTIDEPRESSANTS, SSRIs			
fluoxe fluvox paroxi	lopram tine capsules amine etine CR etine IR	CELEXA (citalopram) fluoxetine DR fluvoxamine ER LEXAPRO (escitalopram) LUVOX (fluvoxamine) paroxetine suspension PAXIL CR (paroxetine) PAXIL SUPENSION (paroxetine) PAXIL Tablets (paroxetine) PEXEVA (paroxetine) PROZAC (fluoxetine) SARAFEM (fluoxetine) ZOLOFT (sertraline)	 Minimum Age Limit 6 years - Zoloft 7 years - Prozac 8 years - Luvox 12 years - Lexapro 18 years - Celexa, Luvox CR, Paxil, Pexeva, Prozac 90 mg Citalopram Criteria <18 years and 90 consecutive days on citalopram in the past 105 days OR < 60 years AND max daily dose ≤ 40 mg/day OR ≥ 60 years AND max daily dose ≤ 20 mg/day Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days

19

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

ANTIEMETICS SmartPA			
	ondansetron ODT ondansetron solution	ANZEMET (dolasetron) granisetron SANCUSO (granisetron) ZOFRAN (ondansetron) ZOFRAN ODT (ondansetron) ZUPLENZ (ondansetron)	Quantity Limit• 4 tablets/28 days - Varubi• 6 tablets/31 days - Akynzeo• 30 tablets/31 days - Zofran tablets/ODT• 100 ml/31 days - Zofran solutionNon-Preferred Agents• Have tried 1 preferred agent in the past 6 monthsInjectables in this class closed to point of sale. PA required if not administered in clinic/hospital
	ANTIEMETIC	COMBINATIONS	
		AKYNZEO (netupitant/palonosetron) BONJESTA (doxylamine/pyridoxine) DICLEGIS (doxylamine/pyridoxine) doxylamine/pyridoxine	Akynzeo - MANUAL PA
	CANNA	BINOIDS	
		CESAMET (nabilone) MARINOL (dronabinol) dronabinol SYNDROS (dronabinol)	
NMDA RECEPTOR ANTAGONIST			
	EMEND (aprepitant)	aprepitant VARUBI (rolapitant)	Varubi - <u>MANUAL PA</u>
ANTIFUNGALS (Oral) SmartPA			

20

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

clotrimazole fluconazole griseofulvin microsize suspen nystatin terbinafine	ANCOBON (flucytosine) ^ CRESEMBA (isavuconazonium) DIFLUCAN (fluconazole) flucytosine GRIFULVIN V (griseofulvin, microsi griseofulvin microsize tablets griseofulvin ultramicrosize tablet GRIS-PEG (griseofulvin) itraconazole ^ ketoconazole LAMISIL (terbinafine) NOXAFIL (posaconazole) ^ ONMEL (itraconazole) ^ SPORANOX (itraconazole) ^ TERBINEX Kit (terbinafine/ciclopiro TOLSURA (itraconazole) VFEND (voriconazole) ^ voriconazole ^	 <u>Smart PA will automatically be</u> <u>issued for this age range</u> Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months <u>HIV opportunistic infection</u> Non-Preferred agent indicated for treatment (^) AND
---	--	---

21

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee. **PREFERRED BRANDS will not count toward the two brand monthly Rx limit.**

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

Have tried 2 different preferred

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		agents in the past 6 months
ANTIFUNGALS (Topical) SmartPA		
· · · /	ANTIFUNGALS	
ciclopirox cream/gel/solution/suspension clotrimazole cream/solution ^{Rx & OTC} ketoconazole shampoo miconazole cream/powder ^{OTC} nystatin terbinafine cream/spray ^{OTC} tolnaftate cream/powder/spray ^{OTC}	BENSAL HP (benzoic acid/salicylic acid) butenafine CICLODAN KIT (ciclopirox kit) ciclopirox kit/shampoo CNL 8 (ciclopirox) econazole ERTACZO (sertaconazole) EXELDERM (sulconazole) EXTINA (ketoconazole) JUBLIA (efinaconazole) KERYDIN (tavaborole) ketoconazole cream ketoconazole foam LAMISIL (terbinafine) solution LOPROX (ciclopirox) LUZU (luliconazole) MENTAX (butenafine) naftifine NAFTIN (naftifine) NIZORAL (ketoconazole) oxiconazole OXISTAT (oxiconazole) PEDIADERM AF (nystatin) PENLAC (ciclopirox) VUSION (miconazole/petrolatum/zinc oxide)	Non-Preferred Criteria • Have tried 2 different preferred agents in the past 6 months

22

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	anty. However, they must adhere to Medicald STA e		
		ROID COMBINATIONS	
	clotrimazole/betamethasone cream	clotrimazole/betamethasone lotion	
	nystatin/triamcinolone	LOTRISONE (clotrimazole/betamethasone)	
ANTIFUNGALS (VAGI	NAL)		
	clotrimazole vaginal cream ^{OTC} miconazole 1, 7cream ^{OTC} TERAZOL 3 Cream (terconazole) – currently unavailable from manufacturer tioconazole	GYNAZOLE 1 (butoconazole) miconazole 3 vaginal cream, suppository ^{OTC} TERAZOL 3 Suppository (terconazole) TERAZOL 7 (terconazole) terconazole	
ANTIHISTAMINES, MI	NIMALLY SEDATING AND COMBINAT	IONS SmartPA	
		ING ANTIHISTAMINES	
	cetirizine tablets ^{OTC} cetirizine syrup ^{Rx & OTC} loratadine odt ^{OTC} loratadine syrup ^{OTC} loratadine tablet ^{OTC}	cetirizine chewable ^{OTC} CLARINEX (desloratadine) desloratadine ODT desloratadine tablet fexofenadine syru fexofenadine table levocetirizine syrup levocetirizine tablet XYZAL Solution (levocetirizine) XYZAL Tablets (levocetirizine)	 Non-Preferred Criteria Documented diagnosis of allergy or urticaria AND Have tried 2 different preferred agents in the past 12 months
		INE/DECONGESTANT COMBINATIONS	
	cetirizine/pseudoephedrine loratadine/pseudoephedrine	ALLEGRA-D (fexofenadine/ pseudoephedrine) CLARITIN-D (loratadine/pseudoephedrine) CLARINEX-D (desloratadine/ pseudoephedrine) fexofenadine/pseudoephedrine ZYRTEC-D (cetirizine/pseudoephedrine)	

23

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

ANTIMIGRAINE AGENTS, CALCITONIN GENE RELATED PEPTIDE INHIBITOR

ORAL			
	NURTEC ODT (rimegepant)**	UBRELVY (ubrogepant)	 Minimum Age Limit 18 years – Nurtec ODT, Ubrelvy Quantity Limit 8 tablets/31 day – Nurtec ODT 16 tablets/31 day – Ubrelvy Nurtec ODT Documented diagnosis of migraine AND Have tried 2 different triptans in the past 6 months AND No concurrent therapy with another CGRP agent Have tried 2 different triptans in the past 6 months AND Have tried 2 different triptans in the past 6 months AND No concurrent therapy with another CGRP agent Have tried preferred Nurtec ODT in the past 6 months AND Have tried preferred Nurtec ODT in the past 6 months AND No concurrent therapy with another CGRP agent AND No concurrent therapy with a strong CYP3A4 inhibitor

24

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	INJECTIBLES	
	AIMOVIG (erenumab-aooe) AJOVY (fremanezumab-vfrm) EMGALITY (galcanezumab-gnlm) VYEPTI (eptinezumab-jjmr)	
ANTIMIGRAINE AGENTS, TRIPTANS & RE	LATED AGENTS ^{SmartPA}	
	ORAL	
naratriptan rizatriptan ODT sumatriptan tablets zolmitriptan zolmitriptan ODT	almotriptan AMERGE (naratriptan) AXERT (almotriptan) eletriptan FROVA (frovatriptan) frovatriptan IMITREX (sumatriptan) MAXALT (rizatriptan) MAXALT MLT(rizatriptan) RELPAX (eletriptan) REYVOW (lasmiditan) TREXIMET (sumatriptan/naproxen) ZOMIG (zolmitriptan)	 Minimum Age Limit – ALL FORMULATIONS 6 years – Maxalt 12-17 years – Axert, Treximet, Zomig nasal spray <u>Smart PA will</u> <u>automatically be issued for this age</u> <u>range</u> 18 years – Amerge, Frova, Imitrex, Onzetra Xsail, Relpax, Reyvow, Tosymra, Zembrace Symtouch, Zomig tablets Quantity Limit - ORAL 4 tablets/31 days – Reyvow 50 mg 6 tablets/31 days – Axert, Relpax Zomig 8 tablets/31 days – Reyvow 100 mg 9 tablets/31 days – Amerge, Frova, Imitrex, Treximet 12 tablets/31 days – Maxalt Non-Preferred Criteria - ORAL Have tried 2 preferred preferred oral agents in the past 90 days

25

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			 Reyvow Documented diagnosis of migraine AND Have tried 2 different triptans in the past 90 days AND Have tried preferred Nurtec ODT in the past 90 days AND
		SAL	
	sumatriptan	IMITREX (sumatriptan) ONZETRA Xsail (sumatriptan)	Quantity Limit - NASAL • 1 box/31 days
		TOSYMRA (sumatriptan)	- I Solid I days
		ZOMIG (zolmitriptan)	 Non-Preferred Criteria - NASAL Have tried 2 preferred oral agents in the past 90 days AND Have tried either a preferred nasal sumatriptan or injectable sumatriptan in the past 90 days
		TABLES	
	sumatriptan	IMITREX (sumatriptan) ZEMBRACE (sumatriptan)	CUMULATIVE Quantity Limit - INJECTION 4 injections/31 days
*ANTINEOPLASTICS –	SELECTED SYSTEMIC ENZYME INHI	IBITORS	
	AFINITOR (everolimus) BOSULIF (bosutinib) CAPRELSA (vandetanib) COMETRIQ (cabozantinib) COTELLIC (cobimetinib) GILOTRIF (afatanib) ICLUSIG (ponatinib) imatinib mesylate IMBRUVICA (ibrutnib) INLYTA (axitinib)	ALECENSA (alectinib) ALUNBRIG (brigatnib) AYVAKIT (avapritinib) BALVERSA (erdafitinib) BRAFTOVI (encorafenib) BRUKINSA (zanubrutinib) COPIKTRA (duvelisib) CABOMETYX (cabozantinib s-malate) CALQUENCE (acalabrutinib) DAURISMO (glasdegib)	 Farydak - MANUAL PA Documented diagnosis of multiple myeloma AND Used in combination with bortezomib and dexamethasone per PI AND History of 2 prior regimens including bortezomib and an immunomodulatory agent

26

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

electronic i ri functional	ity: 110 wever, mey must adhere to weatened birt e		
	IRESSA (gefitinib)	ERLEADA (apalutamide)	
	JAKAFI (ruxolitinib)	FARYDAK (panobinostat)	Ibrance
	MEKINIST (trametinib dimethyl sulfoxide)	GLEEVEC (imatinib mesylate)	 Documented diagnosis of WD-
	NEXAVAR (sorafenib)	GLEOSTINE (lomustine)	DDLS for retroperitoneal sarcoma
	ROZLYTREK (entrectinib)	IBRANCE (palbociclib) SmartPA	OR
	SPRYCEL (dasatinib)	IDHIFA (enasidenib)	 All other indications evaluated
	STIVARGA (regorafenib)	INREBIC (fedratinib)	through clinical review
	SUTENT (sunitinib)	KISQALI (ribociclib)	
	TAFINLAR (dabrafenib)	KOSELUGO (selumetinib)	
	TARCEVA (erlotinib)	LENVIMA (lenvatinib) SmartPA	
	TASIGNA (nilotinib)	LORBRENA (Iorlatinib)	Lenvima
	TURALIO (pexidartinib)	LYNPARZA (olaparib) SmartPA	 Documented diagnosis of thyroid
	TYKERB (lapatinib ditosylate)	MEKTOVI (binimetnib)	cancer OR
	vandetanib	NERLYNX (neratinib maleate)	 Documented diagnosis of
	VOTRIENT (pazopanib)	NUBEQA (darolutamide)	hepatocellular carcinoma OR
	XALKORI (crizotinib)	PEMAZYRE (pemigatinib)	 Documented diagnosis of renal cell
	XTANDI (enzalutamide)	PIQRAY (alpelisib)	carcinoma AND
	ZELBORAF (vemurafenib)	RETEVMO (selpercatinib)	 History of 1 claim for everolimus in
	ZYDELIG (idelalisib)	RUBRACA (rucaparib)	the past 30 days AND
	ZYKADIA (ceritnib)	RYDAPT (midostaurin)	History of 1 anti-angiogenic agent
		TABRECTA (capmatinib)	in the past 2 years.
		TAGRISSO (osimertinib)	
		TALZENNA (talazoparib)	
		TAZVERIK (tazemetostat)	Lynparza Capsules - MANUAL PA
		TIBSOVO (ivosidenib)	
		TUKYSA (tucatinib)	
		VERZENIO (abemaciclib)	Lynparza Tablets
		VITRAKVI (larotrectinib)	 Documented diagnosis of ovarian
		VIZIMPRO (dacomitinib)	cancer, fallopian tube or peritoneal
		XATMEP (methotrexate)	cancer AND
		XOSPATA (gilteritinib)	 History of platinum-based
		XPOVIO (selinexor)	chemotherapy in the past 2 years
		ZEJULA (niraparib)	OR

27

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		All other indications evaluated through clinical review
ANTIPARASITICS (Topical) SmartPA		
P	EDICULICIDES	
permethrin 1% ^{OTC} NATROBA (spinosad)	lindane malathion OVIDE (malathion) SKLICE (ivermectin) spinosad VANALICE (piperonyl butoxide/pyrethrins	 Minimum Age/Weight Limit for Pediculicides 50 kg - lindane shampoo 2 months – permethrin 1%(OTC) 6 months – Natroba, Sklice 2 years – piperonyl/pyrethrins (OTC) 6 years – Ovide Non-Preferred Criteria History of 2 preferred topical lice agents in the past 90 days
	SCABICIDES	
permethrin 5% STROMECTOL Tablet (ivermectin)	ELIMITE (permethrin) EURAX CREAM (crotamiton) EURAX LOTION (crotamiton)	 Minimum Age/Weight Limit for Topical Scabicides 50 kg - lindane lotion 2 months – permethrin 5% 18 years – Eurax Non-Preferred Criteria History of permethrin 5% in the past 90 days
ANTIPARKINSON'S AGENTS (Oral) SmartPA		

28

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	ANTICHOLINERGICS	
benztropine trihexyphenidyl	COGENTIN (benztropine)	 Non-Preferred Criteria Documented diagnosis of Parkinson's disease AND Have tried 2 different preferred agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
	COMT INHIBITORS	
entacapone	COMTAN (entacapone) TASMAR (tolcapone) tolcapone	
	DOPAMINE AGONISTS	
ropinirole	MIRAPEX (pramipexole) MIRAPEX ER (pramipexole) NEUPRO (rotigotine) pramipexole pramipexole ER REQUIP (ropinirole) REQUIP XL (ropinirole) ropinirole ER	
	MAO-B INHIBITORS	
selegiline	AZILECT (rasagiline) ELDEPRYL (selegiline) rasagiline XADAGO (safinamide) ZELAPAR (selegiline)	 Xadago Documented diagnosis of Parkinson's disease AND History of a preferred carbidopa/levodopa combination product in the past 30 days AND History of selegiline product in the past 45 days

29

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	OTHERS	
amantadine bromocriptine carbidopa levodopa/carbidopa	DUOPA (levodopa/carbidopa) GOCOVRI (amantadine) INBRIJA (levodopa) levodopa/carbidopa ODT levodopa/carbidopa/entacapone LODOSYN (carbidopa) NOURIANZ (istradefylline) OSMOLEX ER (amantadine) PARCOPA (levodopa/carbidopa) PARLODEL (bromocriptine) RYTARY ER (levodopa/carbidopa) SINEMET (levodopa/carbidopa) SINEMET CR (levodopa/carbidopa) STALEVO (levodopa/carbidopa)	 Lodosyn and Inbrija Documented diagnosis of Parkinson's disease AND History of a carbidopa/levodopa combination product in the past 45 days Nourianz Documented diagnosis of Parkinson's Disease AND History of a preferred carbidopa/levodopa combination product in the past 30 days AND History of 30 days therapy with a preferred adjunctive therapy in the past 45 days
ANTIPSYCHOTICS SmartPA		
	ORAL	
amitriptyline/perphenazine aripiprazole clozapine fluphenazine haloperidol olanzapine olanzapine ODT perphenazine quetiapine quetiapine XR risperidone	ABILIFY (aripiprazole) ABILIFY MYCITE (aripiprazole) ADASUVE (loxapine) aripiprazole solution aripiprazole ODT CAPLYTA (lumateperone) chlorpromazine clozapine ODT CLOZARIL (clozapine) FANAPT (iloperidone) FAZACLO (clozapine)	 Minimum Age Limit 2 years – Droperidol 3 years – Haldol 5 years – Risperdal, thioridazine 6 years – Abilify,trifluoperazine 10 years – Latuda, Saphris, Seroquel, Symbyax 12 years – Molidone, perphenazine, pimozole, thiothixene 13 years – Zyprexa

30

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

risperidone ODT SAPHRIS (asenapine) thioridazine thiothixene trifluoperazine ziprasidone	GEODON (ziprasidone) HALDOL (haloperidol) INVEGA ER(paliperidone) LATUDA (lurasidone) NUPLAZID (pimavanserin) olanzapine/fluoxetine paliperidone ER REXULTI (brexpiprazole) RISPERDAL (risperidone) SEROQUEL (quetiapine) SEROQUEL XR (quetiapine) SYMBYAX (olanzapine/fluoxetine) VERSACLOZ (clonazpine) VRAYLAR (cariprazine) ZYPREXA (olanzapine)	 18 years – Abilify Mycite, Amitriptyline/perphenazine, Caplyta, Clozaril, Fanapt, fluphenazine, Geodon, Invega, loxapine, Nuplazid, Rexulti, Secuado, Vraylar, Concurrent Therapy Limit – Ages 0-17 years 90 days with >2 antipsychotics in the last 120 days will require a Manual PA Non-Preferred Criteria- Atypical Agents Have tried 2 preferred atypical antipsychotic agents in the past 12 months OR 30 consecutive days on the requested atypical agent in the past 180 days Nuplazid Documented diagnosis of Parkinson's disease
INJECTABLE, AT	TYPICALS SmartPA	
ARISTADA ER (aripiprazole lauroxil) ARISTADA INITIO (aripiprazole lauroxil) ABILIFY MAINTENA (aripirazole) INVEGA SUSTENNA (paliperidone palmitate) INVEGA TRINZA (paliperidone) PERSERIS (risperidone)	ABILIFY (aripiprazole) GEODON (ziprasidone) olanzapine ZYPREXA (olanzapine) ZYPREXA RELPREVV (olanzapine)	Minimum Age Limit • 18 years – all injectable agents Quantity Limit • 3 syringes/year – Aristada Initio

31

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

-have electronic PA functionality. Ho	tion (SmartPA) is a proprietary electronic prior owever, they must adhere to Medicaid's PA cri ERDAL CONSTA (risperidone)	r authorization system used for Medicaid fee for serviteria.	vice claims. MSCAN plans may/may not
			Long Acting Injectable Agents
			 All Agents Documented diagnosis of schizophrenia or schizoaffective disorder
			Abilify Maintena or Risperdal Consta
			 Documented diagnosis of schizophrenia or schizoaffective disorder OR Documented diagnosis of bipolar disorder
	TRANSDERMA		
		SECUADO (asenapine)	
ANTIRETROVIRALS SmartPA			
	SINGLE TABL	ET REGIMENS	
BIKTA DELS GENV (elv ODEF SYMF	PLA (efavirenz/emtricitabine/tenofovir) ARVY (bictegravir/emtricitabine/tenofovir) TRIGO (doravirine/lamivudine/tenofovir)	COMPLERA (emtricitabine/rilpivirine/tenofovir) DOVATO (dolutegravir/lamivudine) JULUCA (dolutegravir/rilpivirine) STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) SYMTUZA (darunavir/cobicistat/ emtricitabine/tenofovir) TRIUMEQ (abacavir/lamivudine/ dolutegravir)	 Stribild – MANUAL PA Genotype testing supporting resistance to other regimens OR Intolerance or contraindication to preferred combination of drugs AND Medical reasoning beyond convenience or enhanced
	· · · · · · · · · · · · · · · · · · ·		22

32

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries) Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not

-have electronic PA functionality. However, they must adhere to Medicai	· · · ·	
		compliance over preferred agents AND • CrCl > 70mL/min to initiate therapy OR CrCl >50mL/min to continue therapy
INTEGRASE S	TRAND TRANSFER INHIBITORS	
ISENTRESS (raltegravir potassium) TIVICAY (dolutegravir sodium)	ISENTRESS HD (raltegravir potassium) VITEKTA (elvitegravir)	 Non-Preferred Criteria 1 claim with the requested agent in the past 105 days
NUCLEOSIDE REVERS	SE TRANSCRIPTASE INHIBITORS (NRTI)	. ,
abacavir sulfate EMTRIVA (emtricitabine) Iamivudine tenofovir disoproxil fumarate ZIAGEN Solution (abacavir sulfate) zidovudine	didanosine DR capsule EPIVIR (lamivudine) RETROVIR (zidovudine) stavudine VIDEX EC (didanosine) VIDEX SOLUTION (didanosine) VIREAD (tenofovir disoproxil fumarate) ZERIT (stavudine) ZIAGEN Tablet (abacavir sulfate)	
NON-NUCLEOSIDE REVE	RSE TRANSCRIPTASE INHIBITOR (NNRTI)	
EDURANT (rilpivirine) SUSTIVA (efavirenz)	efavirenz INTELENCE (etravirine) nevirapine nevirapine ER PIFELTRO (doravirine) RESCRIPTOR (delavirdine mesylate) VIRAMUNE (nevirapine) VIRAMUNE ER (nevirapine)	
PHARMACOENHAN	CER – CYTOCHROME P450 INHIBITOR	

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F

33



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		TYBOST (cobicistat)	Tybost - <u>MANUAL PA</u>	
	PROTEASE INHIB	ITORS (PEPTIDIC)		
	atazanavir EVOTAZ (atazanavir/cobicistat) NORVIR SOLUTION (ritonavir) ritonavir	CRIXIVAN (indinavir) fosamprenavir INVIRASE (saquinavir mesylate) LEXIVA (fosamprenavir) NORVIR POWDER(ritonavir) NORVIR TABLET (ritonavir) REYATAZ (atazanavir) VIRACEPT (nelfinavir mesylate)		
		ORS (NON-PEPTIDIC)		
	PREZISTA (darunavir ethanolate)	APTIVUS (tipranavir) PREZCOBIX (darunavir/cobicistat)		
	ENTRY INHIBITORS - CCR5 C	O-RECEPTOR ANTAGONISTS		
		SELZENTRY (maraviroc)		
	ENTRY INHIBITORS -	- FUSION INHIBITORS		
		FUZEON (enfuvirtide)		
	COMBINATION P	RODUCTS - NRTIS		
	abacavir/lamivudine lamivudine/zidovudine	abacavir/lamivudine/zidovudine COMBIVIR (lamivudine/zidovudine) DOVATO (dolutegravir/lamivudine) EPZICOM (abacavir/lamivudine) JULUCA (dolutegravir/rilpivirine) TRIZIVIR (abacavir/lamivudine/zidovudine)		
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOG RTIS				

34

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

-nave electronic PA functiona	lifty. However, they must adhere to Medicaid's PA c	priteria.	
	DESCOVY (emtricitabine/tenofovir alafenam) TRUVADA (emtricitabine/tenofovir)		
		NUCLEOTIDE ANALOGS & NON-NUCLEOSIDE RTIs	
	ATRIPLA (efavirenz/emtricitabine/tenofovir) CIMDUO (lamivudine/tenofovir) DELSTRIGO (doravirine/lamivudine/tenofovir) ODEFSEY (emtricitabine/rilpivirine/tenofovir AF)	COMPLERA (emtricitabine/rilpivirine/tenofovir) TEMIXYS (lamivudine/tenofovir)	
	COMBINATION PRODUCT	S – PROTEASE INHIBITORS	
	KALETRA (lopinavir/ritonavir)	lopinavir/ritonavir	
	CD4 DIRECTED I	HIV-1 INHIBITOR	
	TROGARZO (ibalizumab)		
ANTIVIRALS (Oral)			
	ANTI-CYTOMEGA	ALOVIRUS AGENTS	
	valganciclovir tablets	PREVYMIS (letermovir) VALCYTE (valganciclovir) valganciclovir solution	valganciclovir solution – automatic approval for age <12 years
			 Prevymis Prevention (prophylaxis) of cytomegalovirus (CMV) infection and disease 18 years or older AND Post hematopoietic stem cell transplant (HSCT) within the past 28 days AND

35

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

CMV sero-positive recipient

.

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			 CMV sero-positive recipient [R+] AND NO severe (Child-Pugh Class C) hepatic impairment
ANTI-HERPETIC AGENTS			
	acyclovir valacyclovir	famciclovir FAMVIR (famciclovir) SITAVIG (acyclovir) VALTREX (valacyclovir) ZOVIRAX (acyclovir)	
ANTI-INFLUENZA AGENTS			
	oseltamivir TAMIFLU (oseltamivir)	FLUMADINE (rimantadine) RAPIVAB (peramivir) RELENZA (zanamivir) rimantadine XOFLUZA (baloxavir marboxil)	
ANTIVIRALS (Topical)			
	ZOVIRAX Cream (acyclovir)	acyclovir cream, ointment DENAVIR (penciclovir) XERESE (acyclovir/hydrocortisone) ZOVIRAX Ointment (acyclovir)	
AROMATASE INHIBITORS			
	anastrozole exemestane letrozole	ARIMIDEX (anastrozole) AROMASIN (exemestane) FEMARA (letrozole)	
ATOPIC DERMATITIS SmartPA			

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F


36



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.



BETA BLOCKERS, ANTIANGINALS & SINUS NODE AGENTS^{SmartPA}

37

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

acebutolol atenolol bisoprolol BYSTOLIC (nebivolol) ^{Step Edit} metoprolol ER nadolol pindolol propranolol ER sotalol	BETAPACE (sotalol) betaxolol CORGARD (nadolol) HEMANGEOL (propranolol) INDERAL LA (propranolol) INDERAL XL (propranolol) INNOPRAN XL (propranolol) KAPSPARGO SPRINKLES (metoprolol) KERLONE (bextaxolol) LEVATOL (penbutolol) LOPRESSOR (metoprolol) SECTRAL (acebutolol) SOTYLIZE (sotalol) TENORMIN (atenolol) TOPROL XL (metoprolol) ZEBETA (bisoprolol)	 Bystolic 90 consecutive days on the requested agent in the past 105 days OR Have tried 1 preferred agent in the past 6 months Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
	BETA- AND ALPHA-BLOCKERS	
carvedilol labetalol	carvedilol CR COREG (carvedilol) COREG CR (carvedilol) TRANDATE (labetalol)	 Coreg CR Documented diagnosis for hypertension AND Have tried generic carvedilol AND 1 preferred agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
BE	TA BLOCKER/DIURETIC COMBINATIONS	
atenolol/chlorthalidone bisoprolol/HCTZ metoprolol/HCTZ nadolol/bendroflumethiazide propranolol/HCTZ timolol/HCTZ	CORZIDE (nadolol/bendroflumethiazide) DUTOPROL (metoprolol/HCTZ) LOPRESSOR HCT (metoprolol/HCTZ) TENORETIC (atenolol/chlorthalidone) ZIAC (bisoprolol/HCTZ)	

38

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	ANTIAI		Banava
		RANEXA (ranolazine) ranolazine	 Ranexa Documented diagnosis of angina AND 1 claim for a calcium channel blocker, beta-blocker, nitrate, or combination agent in the past 30 days OR 90 consecutive days on the requested agent in the past 105 days
	SINUS NO	DE AGENTS	
		CORLANOR (ivabradine)	Corlanor - MANUAL PA
BILE SALTS			
	ursodiol	ACTIGALL (ursodiol) CHENODAL (chenodiol) CHOLBAM (cholic acid) OCALIVA (obeticholic acid) URSO (ursodiol) URSO FORTE (ursodiol)	
BLADDER RELAXANT	PREPARATIONS SmartPA		
	oxybutynin ER oxybutinin IR solifenacin	darifenacin DETROL (tolterodine) DETROL LA (tolterodine) DITROPAN XL (oxybutynin) ENABLEX (darifenacin)	 Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months

39

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

> GELNIQUE (oxybutynin) MYRBETRIQ (mirabegron) OXYTROL (oxybutynin) tolterodine tolterodine ER TOVIAZ (fesoterodine fumarate) trospium trospium ER VESICARE (solifenacin)

BONE RESORPTION SUPPRESSION AND RELATED AGENTS SmartPA

BISPHOSI	PHONATES	
alendronate ibandronate risedronate	ACTONEL (risedronate) ACTONEL WITH CALCIUM (risedronate/calcium) alendronate solution ATELVIA (risedronate) BINOSTO (alendronate) BONIVA (ibandronate) DIDRONEL (etidronate) FOSAMAX (alendronate) FOSAMAX PLUS D (alendronate/vitamin D) risedronate DR Tablet	 Non-Preferred Criteria Documented diagnosis for osteoporosis or osteopenia AND Have tried 2 different preferred agents in the past 6 months
OTH	IERS	
	calcitonin salmon EVENITY (romosozumab-aqqg) EVISTA (raloxifene) FORTEO (teriparatide) MIACALCIN (calcitonin) PROLIA (denosumab) raloxifene	

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F

40



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a p -have electronic PA functionality. However, they must ad	roprietary electronic prior authorization system used for Medicaid a here to Medicaid's PA criteria.	fee for service claims. MSCAN plans may/may not
	TYMLOS (abaloparatide) XGEVA (denosumab)	
BPH AGENTS SmartPA		
	ALPHA BLOCKERS	
alfuzosin doxazosin tamsulosin terazosin	CARDURA (doxazosin) CARDURA XL (doxazosin) dutasteride/tamsulosin FLOMAX (tamsulosin) HYTRIN (terazosin) JALYN (dutasteride/tamsulosin) RAPAFLO (silodosin) silodosin UROXATRAL (alfuzosin)	 Female Cardura, Flomax, Proscar, terazosin, or Uroxatral AND Documented diagnosis based on a State accepted diagnosis Non-Preferred Criteria - MALE Have tried 2 different preferred agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
	5-ALPHA-REDUCTASE (5AR) INHIBITORS	
finasteride	AVODART (dutasteride) dutasteride PROSCAR (finasteride)	
	PDE5 INHIBITORS	
	CIALIS (tadalafil)	
BRONCHODILATORS & COPD AGENTS		
	ANTICHOLINERGICS & COPD AGENTS	
ATROVENT HFA (ipratrop ipratropium SPIRIVA HANDIHALER (t	INCRUSE ELLIPTA (umeclidinium)	Minimum Age Limit 6 years – Spiriva Respimat Spiriva Respimat

41

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	unty. However, they must adhere to Medicald's FA c		
		SPIRIVA RESPIMAT (tiotropium) ^{SmartPA} TUDORZA PRESSAIR (aclidinium) YUPELRI (revefenacin)	 Automatic approval for <u>></u> 6 years with a diagnosis of asthma
	albuterol/ipratropium BEVESPI (glycopyrrolate/formoterol)	ANORO ELLIPTA (umeclidinium/vilanterol) DUAKLIR PRESSAIR (aclidinium/formoterol)	
	COMBIVENT RESPIMAT (albuterol/ipratropium) SmartPA	STIOLTO RESPIMAT (tiotropium/olodaterol) TRELEGY ELLIPTA (fluticasone furoate/	
	UTIBRON (indacaterol/glycopyrrolate)	umeclidinium/vilanterol)	
BRONCHODILATORS	, BETA AGONIST		
	INHALERS, S	HORT-ACTING	
	albuterol HFA PROAIR RESPICLICK (albuterol)	Levalbuterol HFA PROAIR DIGIHALER (albuterol) PROAIR HFA (albuterol) PROVENTIL HFA (albuterol) VENTOLIN HFA (albuterol) XOPENEX HFA (levalbuterol) SmartPA	 Minimum Age Limit 4 years - Xopenex HFA Xopenex HFA 1 claim for a preferred albuterol inhaler in the past 30 days ProAir Digihaler Requires clinical review
	INHALERS, LON	G ACTING ^{SmartPA}	
	SEREVENT (salmeterol)	ARCAPTA (indacaterol) STRIVERDI RESPIMAT (olodaterol)	 Minimum Age Limit 4 years – Serevent 18 years – Arcapta, Striverdi Respimat

42

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			 Documented diagnosis of COPD AND Have tried 1 preferred agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
	INHALATION SC	DLUTION SmartPA	
	albuterol	BROVANA (arformoterol) levalbuterol metaproterenol PERFOROMIST (formoterol) XOPENEX (levalbuterol)	 Minimum Age Limit 6 years – Xopenex 18 years – Brovana, Perforomist Non-Preferred Criteria 1 claim for a different preferred agent in the past 6 months OR 3 claims with the requested agent in the past 105 days Xopenex 1 claim for a preferred albuterol in the past 30 days
	O	RAL	
	albuterol ER albuterol IR metaproterenol terbutaline	VOSPIRE ER (albuterol)	
CALCIUM CHANNEL B	LOCKERS SmartPA		

43

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

SHORT	-ACTING	
diltiazem nicardipine nifedipine verapamil	CALAN (verapamil) CARDIZEM (diltiazem) isradipine nimodipine NYMALIZE SOLUTION (nimodipine) PROCARDIA (nifedipine)	 Quantity Limit - nimodipine 252 tablets/ 21 days 2520 mL/21 days Non-Preferred Criteria Have tried 2 different preferred <u>Short Acting</u> CCB agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days nimodipine Documented diagnosis of subarachnoid hemorrhage in the past 45 days AND Duration of therapy limited to 21 days
LONG	ACTING	
amlodipine DILT XR 24 HR Caps (diltiazem) diltiazem ER Cap 24 HR (generic Cardizem CD) diltiazem ER Cap 24 HR felodipine ER nifedipine ER verapamil ER	ADALAT CC (nifedipine) CALAN SR (verapamil) CARDENE SR (nicardipine) CARDIZEM CD (diltiazem) CARDIZEM LA (diltiazem) DILACOR XR (diltiazem) diltiazem ER Cap 12 HR diltiazem ER Tab 24 HR KATERZIA (amlodipine) nisoldipine NORVASC (amlodipine) PROCARDIA XL (nifedipine) SULAR (nisoldipine)	 Non-Preferred Criteria Have tried 2 different preferred <u>Long Acting</u> CCB agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F

44



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

		TIAZAC (diltiazem) verapamil ER PM VERELAN/VERELAN PM (verapamil)	
ALORIC AGE	NTS		
	BOOST (includes all Boost) BREAKFAST ESSENTIALS BRIGHT BEGINNINGS DUOCAL ENSURE GLUCERNA NUTREN (includes all Nutren) OSMOLITE PEDIASURE PROMOD RESOURCE SCANDISHAKE TWOCAL HN	All other products (caloric /nutritional agents) not listed as preferred will require a manual prior authorization.	Non-Preferred Agents - <u>MANUA</u> <u>PA</u>
CEPHALOSPO	RINS AND RELATED ANTIBIOTICS (O	Pral)	
	BETA LACTAM/BETA	-LACTAMASE INHIBITOR COMBINATIONS	
	amoxicillin/clavulanate amoxicillin/clavulanate XR	AUGMENTIN 125 and 250 Suspension (amoxicillin/clavulanate) AUGMENTIN (amoxicillin/clavulanate) Tablets AUGMENTIN XR (amoxicillin/clavulanate) MOXATAG (amoxicillin)	
	CEPHALOSP	ORINS – First Generation SmartPA	
	cefadroxil cephalexin capsules	cephalexin tablets DAXBIA (cephalexin)	Non-Preferred Criteria – all generations

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

-nave electronic FA functi	onality. However, they must adhere to Medicaid's PA	cificilia.	
	cephalexin suspension	KEFLEX (cephalexin)	Have tried 2 different preferred agents in the past 6 months
	CEPHALOSPORINS – S	Second Generation SmartPA	
	cefaclor capsules	cefaclor ER	
	cefprozil	cefaclor suspension	
	cefuroxime tablets	cefuroxime suspension	
		CEFTIN (cefuroxime)	
	CEPHALOSPORINS -	Third Generation SmartPA	
	cefdinir suspension	CEDAX (ceftibuten)	Maximum Age Limit
	cefdinir capsules	cefditoren	 18 years – cefdinir suspension
	cefpodoxime	ceftibuten	
		SPECTRACEF (cefditoren)	
		SUPRAX (cefixime)	
COLONY STIMULAT	ING FACTORS		
	GRANIX (tbo-filgrastim)	FULPHILA (pegfilgrastim)	
	NEUPOGEN Syringe (filgrastim)	LEUKINE (sargramostim)	
	NEUPOGEN Vial (filgrastim)	NEULASTA (pegfilgrastim)	
		NIVESTYM (filgrastim-aafi)	
		UDENYCA (pegfilgrastim-cbqv)	
		ZARXIO (filgrastim)	
		ZIEXTENZO (pegfilgrastim-bmez)	
	GENTS SmartPA		
	BETHKIS (tobramycin)	CAYSTON (aztreonam)	Minimum Age Limit
	KITABIS (tobramycin)	COLY-MYCIN M (colistimethate sodium)	• 3 months – Pulmozyme
	tobramycin(generic TOB I) labeler 00093,00781,	KALYDECO (ivacaftor)	• 4 months – Kalydeco Granules
	17478, 43598, 65162, 68180	ORKAMBI (lumacaftor/ivacaftor)	• 2 years – Coly-Mycin M, Orkambi
		PULMOZYME (dornase alfa) SYMDEKO (tezacaftor/ivacaftor)	Granules
		TOBI (tobramycin)	• 6 years – Bethkis, Kalydeco Tablet,
			Kitabis, Orkambi 100/125mg

46

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.


A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.



47

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		OLUMIANT (baricitinib) ORENCIA (abatacept) OTEZLA (apremilast) OTREXUP (methotrexate) RASUVO (methotrexate) REMICADE (infliximab) RENFLEXIS (infliximab-abda) RHEUMATREX (methotrexate) RINVOQ (upadacitinib) SILIQ (brodalumab) SILIQ (brodalumab) SIMPONI (golimumab) STELARA (ustekinumab) TALTZ (ixekizumab) TREMFYA (guselkumab) TREMFYA (guselkumab) TREXALL (methotrexate) XELJANZ (tofacitinib) XELJANZ XR (tofacitinib)	 Verified clinic administered first doses do not negate the preferred/nonpreferred status. ** Non-preferred agents will require a trial and failure of 2 preferred products for approval and will be evaluated through clinical review. Cosentyx ≥ 18 years = Minimum Age Documented diagnosis of plaque psoriasis, psoriatic arthritis or ankylosing spondylitis in the past 2 years AND 90 consecutive days of Humira in the past year
ERYTHROPOIESIS ST	MULATING PROTEINS SmartPA		
	EPOGEN (rHuEPO) MIRCERA (methoxy polyethylene glycol-epoetin- beta) RETACRIT (rHuEPO)	ARANESP (darbepoetin) PROCRIT (rHuEPO)	 Mircera Documented diagnosis chronic renal failure in the past 2 years Non-Preferred Criteria Documented diagnosis of cancer or chronic renal failure OR Antineoplastic therapy in the past 6 months AND Trial of a preferred Retacrit or Epogen in the past 6 months OR

48

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

• 1 claim for the requested agent in the past 105 days

FACTOR DEFICIENCY PRODUCTS

FAC	TOR VIII
ADVATE AFSTYLA ALPHANATE FEIBA NF HEMOFIL M HUMATE-P KOATE KOGENATE FS NOVOEIGHT NUWIQ RECOMBINATE WILATE XYNTHA XYNTHA SOLOFUSE	ADYNOVATE ELOCTATE ESPEROCT JIVI KCENTRA KOVALTRY NOVOSEVEN RT OBIZUR VONVENDI
FAC	TOR IX
ALPHANINE SD ALPROLIX BENEFIX IXINITY MONONINE PROFILNINE RIXUBIS	IDELVION REBINYN

49

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	OTHER FAC	FOR PRODUCTS	 Hemlibra 1 claim with the requested agent in the past 105 days MANUAL PA – new patients
	COAGADEX FIBRYGA RIASTAP	CORIFACT HEMLIBRA ^{SmartPA} TRETTEN	
FIBROMYALGIA/NEU	ROPATHIC PAIN AGENTS		
	duloxetine gabapentin pregabalin SAVELLA (milnacipran)	CYMBALTA (duloxetine) ^{SmartPA} duloxetine DR GRALISE (gabapentin) HORIZANT (gabapentin) IRENKA (duloxetine) ^{SmartPA} LYRICA (pregabalin) LYRICA CR (pregabalin) NEURONTIN (gabapentin)	Cymbalta and Irenka (see Antidepressant, Other) Minimum Age Limit – automatic approval for ages 7-17 with a diagnosis of GAD (Generalized Anxiety Disorder) for preferred duloxetine
FLUOROQUINOLONE	S (Oral) ^{SmartPA}		
	ciprofloxacin tablets levofloxacin tablets	AVELOX (moxifloxacin) BAXDELA (delaflozacin) CIPRO (ciprofloxacin) CIPRO SUSPENSION (ciprofloxacin) CIPRO XR (ciprofloxacin) ciprofloxacin ER ciprofloxacin suspension FACTIVE (gemifloxacin) LEVAQUIN (levofloxacin) levofloxacin solution	 Non-Preferred Criteria 1 claim for a preferred agent in past 30 days Cipro Suspension for age < 12 years Anthrax infection or exposure OR Cystic Fibrosis OR Pneumonic plague OR tularemia AND history of doxycycline in the past 3 months OR

50

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		moxifloxacin NOROXIN (norfloxacin) ofloxacin	 7 days of therapy with a preferred agent from 2 of the classes below in the past 3 months Penicillin, 2nd or 3rd generation cephalosporin, or macrolide Levaquin solution for age < 12 years Anthrax infection or exposure OR 7 days of therapy with a preferred agent from 2 of the classes below in the past 3 months Penicillin, 2nd or 3rd generation cephalosporin, or macrolide Compared the classes below in the past 3 months Penicillin, 2nd or 3rd generation cephalosporin, or macrolide AND Cipro suspension in the past 3 months Months Cipro suspension in the past 3 months Months 	
GAUCHER'S DISEASE				
	ELELYSO (taliglucerase alfa) ZAVESCA (miglustat)	CERDELGA (eliglustat) CEREZYME(imiglucerase) miglustat VPRIV (velaglucerase alfa)		
GENITAL WARTS & ACTINIC KERATOSIS AGENTS				
	ALDARA (imiquimod) ^{Age Edit} CONDYLOX (podofilox) ^{Age Edit} podofilox Age Edit	CARAC (fluorouracil) diclofenac 3% gel imiquimod ^{Age Edit} EFUDEX (fluorouracil) fluorouracil 0.5% cream fluorouracil 5% cream PICATO (ingenol) ^{Age Edit} SOLARAZE (diclofenac)	 Minimum Age Limit 12 years – Aldara 18 years – Condylox, Picato, Veregen 	

51

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not				
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.				
TOLAK (fluorouracil)				

GLUCOCORTICOIDS		ORTICOIDS ALVESCO (ciclesonide) ARMONAIR Digihaler (fluticasone) ARNUITY ELLIPTA (fluticasone) ASMANEX HFA (mometasone) budesonide 1mg PULMICORT (budesonide) Respules	 Non-Preferred Criteria 90 consecutive days on the requested agent in the past 105 days OR Have tried 1 preferred agent in the past 6 months ArmonAir Digihaler Requires clinical review <u>NOTE:</u> Institutional sized products are Non-Preferred
	GLUCOCORTICOID/BRONC	HODILATOR COMBINATIONS	
	ADVAIR HFA (fluticasone/salmeterol) DULERA (mometasone/formoterol) fluticasone/salmeterol SYMBICORT (budesonide/formoterol)	ADVAIR DISKUS (fluticasone/salmeterol) AIRDUO Digihaler (fluticasone/salmeterol) AIRDUO Respiclick (fluticasone/salmeterol) BREO ELLIPTA (fluticasone/vilanterol) budesonide/formoterol WIXELA INHUB (fluticasone/salmeterol)	 Non-Preferred Criteria 90 consecutive days on the requested agent in the past 105 days OR Have tried 2 different preferred agents in the past 6 months AirDuo Digihaler Requires clinical review

52

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

GI ULCER THERAPIES			
	H2 RECEPTOR	ANTAGONISTS	
	cimetidine solution	AXID (nizatidine)	
	famotidine solution	cimetidine tablets	
	famotidine tablets	nizatidine tablets	
	nizatidine solution	PEPCID (famotidine)	
	PROTON PUN	IP INHIBITORS	
	esomeprazole magnesium DR Capsule NEXIUM PACKET (esomeprazole) omeprazole Rx pantoprazole	ACIPHEX SPRINKLE (rabeprazole) ACIPHEX Tablet (rabeprazole) DEXILANT (dexlansoprazole) esomeprazole strontium DR Capsule lansoprazole Rx NEXIUM Rx DR Capsule (esomeprazole) omeprazole sod. bicarb. PREVACID Rx (lansoprazole) PREVACID SOLU-TAB (lansoprazole) PRILOSEC RX (omeprazole) PRILOSEC SUSPENSION (omeprazole) PROTONIX DR (pantoprazole) PROTONIX PACKET (pantoprazole) rabeprazole	Prilosec suspension • Automatic approval for 0 - 2 years
	ОТ	HER	
	CARAFATE SUSPENSION (sucralfate) misoprostol sucralfate tablet	CARAFATE TABLET (sucralfate) CYTOTEC (misoprostol) sucralfate suspension	
GROWTH HORMONE ^S	SmartPA		
	NORDITROPIN (somatropin) NUTROPIN AQ (somatropin)	GENOTROPIN (somatropin) HUMATROPE (somatropin)	All Agents for Age <u>></u> 18 years

53

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		OMNITROPE (somatropin) SAIZEN (somatropin) SEROSTIM (somatropin) ZOMACTON (somatropin) ZORBTIVE (somatropin)	 Documented diagnosis of craniopharyngioma, panhypopituitarism, Prader-Willi Syndrome, Turner Syndrome or an approvable indication OR Documented procedure of cranial irradiation Non-Preferred Criteria Have tried 1 preferred agent in the past 6 months OR 84 consecutive days on the requested agent in the past 105 days
H. PYLORI COMBINAT	ION TREATMENTS		
	PYLERA (bismuth subcitrate potassium, metronidazole, tetracycline)	 Iansoprazole, amoxicillin, clarithromycin OMECLAMOX (omeprazole, clarithromycin, amoxicillin) PREVPAC (lansoprazole, amoxicillin, clarithromycin) TALICIA (omeprazole, amoxicillin, rifabutin) 	Quantity Limit • 1 treatment course/year
HEPATITIS B TREATM	ENTS		
	entecavir EPIVIR HBV SOLUTION (lamivudine) lamivudine HBV tenofovir disoproxil fumarate	adefovir dipivoxil BARACLUDE (entecavir) EPIVIR HBV TABLET (lamivudine) HEPSERA (adefovir dipivoxil) TYZEKA (telbivudine) VEMLIDY (tenofovir alafenamide fumarate) VIREAD (tenofovir disoproxil fumarate)	
HEPATITIS C TREATM			

HEPATITIS C TREATMENTS

54

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	allopurinol colchicine capsule	colchicine tablet COLCRYS (colchicine)	Non-Preferred Criteria
HYPERURICEMIA & GO			New Desferred Onitaria
		BERINERT (C1 esterase inhibitor) CINRYZE VIAL (C1 esterase inhibitor) FIRAZYR SYRINGE (icatibant acetate) HAEGARDA (C1 esterase inhibitor) icatibant KALBITOR VIAL (ecallantide) RUCONEST VIAL (C1 esterase inhibitor, recombinant) TAKHZYRO (lanadelumab-flyo)	
HEREDITARY ANGIOE	DEMA		
	PEGASYS (peginterferon alfa-2a) PEG-INTRON (peginterferon alfa-2b) ribavirin tablets sofosbuvir/velpatasvir∞	DAKLINZA (daclatasvir) ∞ EPCLUSA (sofosbuvir/velpatasvir) ∞ HARVONI (ledipasvir/sofosbuvir)∞ ledipasvir/sofosbuvir∞ MODERIBA (ribavirin) OLYSIO (simeprevir) REBETOL (ribavirin) RIBASPHERE (ribavirin) RIBASPHERE RIBAPAK DOSEPACK (ribavirin) ribavirin capsules SOVALDI (sofosbuvir)∞ TECHNIVIE (ombitasvir/paritaprevir/ritonavir) VIEKIRA (ombitasvir/paritaprevir/ritonavir) VIEKIRA XR (ombitasvir/paritaprevir/ritonavir) VOSEVI (sofosbuvir/velpatasvir/voxilaprevir)∞ ZEPATIER (elbasvir/grazoprevir)∞	 Daklinza, Epclusa, Harvoni, Mavyret, Sovaldi, Vosevi, Zepatier Require clinical review <u>Note</u>: Harvoni and Sovaldi have FDA pediatric indications
	MAVYRET (glecaprevir/pibrentasvir)∞	COPEGUS (ribavirin)	

55

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

-	Application (SmartPA) is a proprietary electronic pri- lity. However, they must adhere to Medicaid's PA c probenecid probenecid/colchicine	or authorization system used for Medicaid fee for serv rriteria. febuxostat LOPERBA (colchicine) MITIGARE (colchicine) ULORIC (febuxostat) ZYLOPRIM (allopurinol)	 vice claims. MSCAN plans may/may not Have tried 2 different preferred agents in the past 6 months
HYPOGLYCEMIA TRE	ATMENT, GLUCAGON		
	BAQSIMI (glucagon) ^{Step Edit} glucagen vial glucagon kit	<mark>GVOKE (glucagon)</mark>	 Minimum Age Limit 2 years – Gvoke 4 years – Baqsimi Quantity Limit 2 packs/31 days – Baqsimi 2 syringes/31days – Gvoke Baqsimi Approved afer a trial and failure of generic
HYPOGLYCEMICS, BI	GUANIDES SmartPA		
	metformin HCL tablet metformin HCL ER 24HR tablet (generic GlucophageXR)	FORTAMET ER GLUCOPHAGE (metformin) GLUCOPHAGE XR (metformin ER) GLUMETZA (metformin ER) metformin 24HR (generic Fortamet) metformin 24 HR(generic Glumetza) RIOMET SOLUTION* (metformin)	 Clinical review required for addition of a fourth concurrent oral agent in a different drug class Concurrent therapy with the incoming claim is defined as 20 or more days' supply of the drug in the past 30 days 2-drug combination agents count as 2 classes and 3-

56

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			drug combination agents count as 3 classes Riomet Solution • 90 consecutive days on the requested agent in the past 105 days
HYPOGLYCEMICS, DPP4s an			
JANUM JANUV JENTAI	ET (sitagliptin/metformin) ET XR (sitagliptin/metformin) IA (sitagliptin) DUETO (linagliptin/metformin) ENTA (linagliptin)	alogliptin alogliptin/metformin alogliptin/pioglitazone JENTADUETO XR (linagliptin/metformin) KAZANO (alogliptin/metformin) KOMBIGLYZE XR (saxagliptin/metformin)* NESINA (alogliptin) ONGLYZA (saxagliptin) * OSENI (alogliptin/pioglitazone)	 Clinical review required with concomitant use of GLP-1 product in the past 30 days OF Addition of a fourth concurrent oral agent in a different drug class Concurrent therapy with the incoming claim is defined a 20 or more days' supply of the drug in the past 30 days 2-drug combination agents count as 2 classes and 3-drug combination agents count as 3 classes Kombiglyze XR and Onglyza 90 consecutive days on the requested agent in the past 10 days
HYPOGLYCEMICS, INCRETIN	I MIMETICS/ENHANCERS	S SmartPA	
BYETT	EON (exenatide) A (exenatide) ZA (liraglutide)	ADLYXIN (lixisenatide) BYDUREON BCISE (exenatide) OZEMPIC (semaglutide)	 Clinical review required with concomitant use of DPP-4 product in the past 30 days OF

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		RYBELSUS (semaglutide) SOLIQUA (insulin glargine/lixisenatide) SYMLIN (pramlintide) TRULICITY (dulaglutide) XULTOPHY (insulin degludec/ liraglutide)	 Addition of a fourth concurrent oral agent in a different drug class Concurrent therapy with the incoming claim is defined as 20 or more days' supply of the drug in the past 30 days 2-drug combination agents count as 2 classes and 3- drug combination agents count as 3 classes Symlin is excluded from all criteria
HYPOGLYCEMICS, IN	SULINS AND RELATED AGENTS Smart	PA	
	HUMULIN N, R, 70/30 VIAL ^{OTC} (insulin) HUMULIN R U500 VIAL (insulin) insulin aspart insulin aspart flexpen insulin aspart mix insulin aspart mix flexpen Insulin lispro insulin lispro kwikpen LANTUS SOLOSTAR & VIAL (insulin glargine) LEVEMIR FLEXPEN & VIAL (insulin detemir)	AFREZZA (insulin) ADMELOG (insulin lispro) APIDRA (insulin gluisine) APIDRA SOLOSTAR (insulin gluisine) BASAGLAR (insulin glargine) FIASP (insulin aspart) HUMALOG JR (insulin lispro) HUMALOG KWIKPEN U100 (insulin lispro) HUMALOG KWIKPEN U200 (insulin lispro) HUMALOG MIX KWIKPEN (insulin lispro/ lispro protamine) HUMALOG MIX VIAL (insulin lispro/ lispro protamine) HUMALOG VIAL (insulin lispro) HUMALOG VIAL (insulin lispro) HUMALOG VIAL (insulin lispro)	 Insulin pen formulations are not covered for Long Term Care (LTC) beneficiaries. Non-Preferred Criteria Documented diagnosis of Diabetes Mellitus AND Have tried 1 preferred product in the past 6 months OR 1 claim with the requested agent in the past 105 days

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F

58



MISSISSIPPI DIVISION OF MEDICAID UNIVERSAL PREFERRED DRUG LIST

EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

•	Application (SmartPA) is a proprietary electronic pri lity. However, they must adhere to Medicaid's PA c	or authorization system used for Medicaid fee for serv riteria. NOVOLIN N, R, 70/30 FLEXPEN (insulin) ^{OTC} NOVOLIN N, R, 70/30 VIAL (insulin) ^{OTC} NOVOLOG FLEXPEN & VIAL (insulin aspart) NOVOLOG MIX FLEXPEN & VIAL (insulin aspart/ aspart protamine) TRESIBA (insulin degludec) TOUJEO (insulin glargine) TOUJEO MAX(insulin glargine)	vice claims. MSCAN plans may/may not	
HYPOGLYCEMICS, ME	GLITINIDES SmartPA			
	nateglinide repaglinide	PRANDIMET (repaglinide/metformin) PRANDIN (repaglinide) repaglinide/metformin STARLIX (nateglinide)	 Clinical review required with addition of a fourth concurrent oral agent in a different drug class Concurrent therapy with the incoming claim is defined as 20 or more days' supply of the drug in the past 30 days 2-drug combination agents count as 2 classes and 3-drug combination agents count as 3 classes 	
HYPOGLYCEMICS, SC	HYPOGLYCEMICS, SODIUM GLUCOSE COTRANSPORTER-2 INHIBITORS SmartPA			
		DSE COTRANSPORTER-2 INHIBITORS		
	FARXIGA (dapagliflozin) JARDIANCE (empagliflozin)	INVOKANA (canagliflozin) STEGLATRO (ertugliflozin)	Clinical review required with addition of a fourth concurrent	

59

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			 oral agent in a different drug class Concurrent therapy with the incoming claim is defined as 20 or more days' supply of the drug in the past 30 days 2-drug combination agents count as 2 classes and 3-drug combination agents count as 3 classes
		RANSPORTER-2 INHIBITOR COMBINATIONS	
	SYNJARDY (empagliflozin/metformin)	GLYXAMBI (empagliflozin/linagliptin) INVOKAMET (canaglifozin/metformin) INVOKAMET XR (canaglifozin/metformin) QTERN (dapaglifozin/saxagliptin) SEGLUROMET (ertugliflozin/metformin) STEGLUJAN (ertugliflozin/sitagliptin) SYNJARDY XR (empagliflozin/metformin) TRIJARDYXR(empagliflozin/linagliptin/metformin) XIGDUO XR (dapaglifozin/metformin)	
HYPOGLYCEMICS, TZI	DS		
	THIAZOLIC	DINEDIONES	
	pioglitazone	ACTOS (pioglitazone) AVANDIA (rosiglitazone)	 Clinical review required for addition of a fourth concurrent oral agent in a different drug class Concurrent therapy with the incoming claim is defined as 20 or more days' supply of the drug in the past 30 days

60

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		 2-drug combination agents count as 2 classes and 3- drug combination agents count as 3 classes
	TZD COMBINATIONS	
pioglitazone/metformin	ACTOPLUS MET (pioglitazone/metformin) ACTOPLUSMET XR (pioglitazone/metformin) AVANDAMET (rosiglitazone/metformin) AVANDARYL (rosiglitazone/glipizide) DUETACT (pioglitazone/glimepiride) pioglitazone/glimepiride	
IDIOPATHIC PULMONARY FIBROSIS SmartPA		
ESBRIET (pirfenidone) OFEV (nintedanib)		 All Agents Documented diagnosis Idiopathic Pulmonary Fibrosis Esbriet & OFEV No concurrent therapy with either agent
IMMUNOSUPPRESSIVE (ORAL) SmartPA		
AZASAN (azathioprine) azathioprine CELLCEPT (mycophenolate) cyclosporine cyclosporine modified GENGRAF (cyclosporine) IMURAN (azathioprine) mycophenolic acid mycophenolate mofetil NEORAL (cyclosporine) RAPAMUNE (sirolimus)	ASTAGRAF XL (tacrolimus) ENVARSUS XR (tacrolimus) HECORIA (tacrolimus) MYFORTIC (mycophenolic acid) PROGRAF (tacrolimus)	 Minimum Age Limit 13 years - Rapamune 18 years - Zortress Astagraf, Cellcept, Envarsus XR, Hecoria, Prograf Documented diagnosis for heart transplant, kidney transplant, liver transplant, or a State accepted diagnosis Azasan

61

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

-	Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not			
-have electronic PA functional	ity. However, they must adhere to Medicaid's PA c	riteria.		
	SANDIMMUNE (cyclosporine) sirolimus tacrolimus		 Documented diagnosis of kidney transplant, RA, or a State accepted diagnosis 	
	ZORTRESS (everolimus)		 Gengraf, Neoral, Sandimmune Documented diagnosis of heart transplant, kidney transplant, liver transplant, psoriasis, RA, or a State accepted diagnosis OR Clinical review required for a diagnosis of Kimura's disease or multifocal motor neuropathy Myfortic Documented diagnosis of kidney transplant or psoriasis 	
			 Rapamune Documented diagnosis of kidney transplant 	
			 Zortress Documented diagnosis of kidney transplant or liver transplant 	
IMMUNE GLOBULINS				
	CARIMUNE NF FLEBOGAMMA DIF GAMASTAN SD GAMMAGARD GAMMAKED GAMUNEX-C HIZENTRA HYQVIA	ASCENIV BIVIGAM CABLIVI CUTAQUIG CUVITRU GAMMAGARD SD GAMMAPLEX PRIVIGEN		

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

62

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic p -have electronic PA functionality. However, they must adhere to Medicaid's PA OCTAGAM PANZYGA XEMBIFY IMMUNOLOGIC THERAPIES FOR ASTHMA FASENRA PEN AUTOINJECTOR (benralizumab)∞ NUCALA AUTOINJECTOR (mepolizumab)∞	-	vice claims. MSCAN plans may/may not
INTRANASAL RHINITIS AGENTS		
ANTICH	OLINERGICS	
ipratropium	ATROVENT (ipratropium)	
ANTIH	ISTAMINES	
azelastine	ASTEPRO (azelastine) olopatadine PATANASE (olopatadine)	
ANTIHISTAMINE/CORTICOS		
	DYMISTA (azelastine/fluticasone) TICALAST (azelastine/fluticasone)	
CORTICOST	EROIDS SmartPA	
fluticasone ^{Rx Only}	BECONASE AQ (beclomethasone) budesonide flunisolide mometasone NASONEX (mometasone) OMNARIS (ciclesonide)	 Non-Preferred Criteria Documented diagnosis for allergic rhinitis AND Have tried 1 different preferred agent in the past 6 months

63

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

-nave electronic PA function	nality. However, they must adhere to Medicaid's P	QNASL (beclomethasone) TICANASE KIT (flonase kit) triamcinolone VERAMYST (fluticasone) XHANCE (fluticasone) ZETONNA (ciclesonide)	
IRON CHELATING AG	GENTS		
	deferasirox all strenghts FERRIPROX (deferiprone)	EXJADE (deferasirox) JADENU (deferasirox) JADENU SPRINKLES (deferasirox)	Jadenu – <u>MANUAL PA</u>
IRRITABLE BOWEL	SYNDROME/SHORT BOWEL SYNDR	OME AGENTS/SELECTED GI AGEN	ITS SmartPA
		SYNDROME CONSTIPATION	
	AMITIZA (lubiprostone) LINZESS 145mcg, 290mcg (linaclotide) MOVANTIK (naloxegol)	LINZESS 72mcg (linaclotide) MOTEGRITY (prucalopride) RELISTOR (methylnaltrexone) SYMPROIC (naldemedine) TRULANCE (plecanatide) ZELNORM (tegaserod)	Minimum Age Limit All Subclasses • 18 years – except Bentyl, Gattex, Levsin Gender Limit • Female – Amitiza 8mcg Chronic Idiopathic Constipation (CIC) AMITIZA 24MCG, LINZESS 72MCG, LINZESS 145 MCG, MOTEGRITY, TRULANCE All CIC Agents:
			 Documented diagnosis of CIC in the past year AND No history of GI or bowel obstruction

64

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

Non-Preferred CIC Agents Above CIC oriteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 106 days Irritable Bowel Syndrome - Constipation Dominant (BS-C) AMITIZA 8MCG, LINZESS 290 MCG, ATTULANCE All IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C criteria AND • No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days. Opticid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • Documented diagnosis of OIC in the past year AND • 1 claim for an optioi in the past 30 days of AND	
 30 days of therapy with 2 preferred agents in the past 105 days Irritable Bowel Syndrome - Constipation Dominant (IBS-C) AMITIZA 8MOG, LINZESS 290 MCG, TRULANCE All IBS-C Agents: Documented diagnosis of IBS-C in the past year AND No history of GI or bowel obstruction Non-Preferred IBS-C Agents Above IBS-C criteria AND No history of GI or bowel obstruction Non-Preferred IBS-C Agents Above IBS-C criteria AND No advas of therapy with 2 preferred agents in the past 5 months OR I claim with the requested agent in the past 105 days MITIZA 24MCG, MOVANTIK, RELISTOR SOR ONCOMENTATION CONTROL CONTRO	
agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Irritable Bowel Syndrome - Constituation Dominant (IBS-C) AMTIZA SMCG, LINZESS 290 MCG, TRULANCE AII IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction • Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMTIZA 24WCG, MOVANTIK, RELISTOR, SYMPROIC AII OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for a opioid in the past 30	 Above CIC criteria AND
agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Irritable Bowel Syndrome - Constituation Dominant (IBS-C) AMTIZA SMCG, LINZESS 290 MCG, TRULANCE AII IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction • Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMTIZA 24WCG, MOVANTIK, RELISTOR, SYMPROIC AII OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for a opioid in the past 30	 30 days of therapy with 2 preferred
 1 claim with the requested agent in the past 105 days Irritable Bowel Syndrome - Constigation Dominant (IBS-C) AMITIZA 8MCG, LINZESS 290 MCG, TRUZANCE All IBS-C Agents: Documented diagnosis of IBS-C in the past year AND No history of GI or bowel obstruction Non-Preferred IBS-C Agents Above IBS-C criteria AND S0 days of therapy with 2 preferred agents in the past 5 months OR 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim with the repast 30 	
the past 105 days Irritable Bowel Syndrome -: Constigation Dominant (IBS-C) AMTIZA SMCG, LIXZESS 200 MCG, TRULANCE All IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
Irritable Bowel Syndrome - Constipation Dominant (IBS-C) AMITIZA 8MCG, LINZESS 290 MCG, TRULANCE Documented diagnosis of IBS-C in the past year AND No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • Documented diagnosis of OIC in the past 30	
Constipation Dominant (IBS-C) AMITIZA 8MCG, LINZESS 290 MCG, TRULANCE AII IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction • Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) ANTIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC AII OIC Agents: • Documented diagnosis of OIC in the past 30	
Constipation Dominant (IBS-C) AMITIZA 8MCG, LINZESS 290 MCG, TRULANCE AII IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction • Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) ANTIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC AII OIC Agents: • Documented diagnosis of OIC in the past 30	Irritable Bowel Syndrome –
AMITIZA 8MCG, LINZESS 290 MCG, TRULANCE All IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opicid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opicid in the past 30	
TRULANCE All IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past 30	
All IBS-C Agents: • Documented diagnosis of IBS-C in the past year AND • No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
 Documented diagnosis of IBS-C in the past year AND No history of GI or bowel obstruction Non-Preferred IBS-C Agents Above IBS-C criteria AND 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	
 Documented diagnosis of IBS-C in the past year AND No history of GI or bowel obstruction Non-Preferred IBS-C Agents Above IBS-C criteria AND 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	All IBS-C Agents:
the past year AND • No history of GI or bowel obstruction Non-Preferred IBS-C Agents • Above IBS-C ariteria AND • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMTIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
 No history of GI or bowel obstruction Non-Preferred IBS-C Agents Above IBS-C criteria AND 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC ODocumented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	
Image: Section of the section of th	
Non-Preferred IBS-C Agents • Above IBS-C criteria AND • 30 days of therapy with 2 preferred agents in the past of therapy with 2 preferred agents in the past of the agents in the past of the agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
 Above IBS-C criteria AND 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	obstruction
 Above IBS-C criteria AND 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	Non Dreferred IDS C Agente
 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	
agents in the past 6 months OR • 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
 1 claim with the requested agent in the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	
the past 105 days Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
Opioid Induced Constipation (OIC) AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	the past 105 days
AMITIZA 24MCG, MOVANTIK, RELISTOR, SYMPROIC All OIC Agents: • Documented diagnosis of OIC in the past year AND • 1 claim for an opioid in the past 30	
RELISTOR, SYMPROIC All OIC Agents:	
 All OIC Agents: Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	
 Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	RELISTOR, SYMPROIC
 Documented diagnosis of OIC in the past year AND 1 claim for an opioid in the past 30 	
the past year AND • 1 claim for an opioid in the past 30	
the past year AND • 1 claim for an opioid in the past 30	 Documented diagnosis of OIC in
• 1 claim for an opioid in the past 30	
	days AND

65

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		 No history of GI or bowel obstruction AND Documented diagnosis of chronic pain in the past year
		 Non- Preferred OIC Agents Above OIC criteria AND 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days
		 Relistor Injection Above OIC criteria AND Documented diagnosis of active cancer in the past year AND Documented diagnosis of palliative care in the past 6 months
IRRITABLE BOWEL S	SYNDROME DIARRHEA	
dicyclomine hyoscyamine	alosetron BENTYL (dicyclomine) LEVSIN (hyoscyamine) LEVSIN-SL (hyoscyamine) LOTRONEX (alosetron) VIBERZI (eluxadoline)*	 Viberzi Documented diagnosis of Irritable Bowel Syndrome – Diarrhea Dominant (IBS-D) in the past year AND 30 days of therapy with 2 preferred agents in the past 6 months OR 1 claim with the requested agent in the past 105 days
		Lotronex

66

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	iteria:	
		 1 claim for the requested agent in the past 105 days OR <u>MANUAL PA</u> - All new patients require manual review. Xifaxan - (<u>see Antibiotics, GI</u>)
SHORT BOWEL SYNDROME	AND SELECTED GI AGENTS	
	FULYZAQ (crofelemer) GATTEX (teduglutide) MYTESI (crofelemer) NUTRESTORE POWDER PACK (glutamine) XERMELO (telotristat ethyl) ZORBTIVE (somatropin)	 Carcinoid Syndrome Agent XERMELO Documented diagnosis of carcinoid syndrome in the past year AND 1 claim for a somatostatin analog in the past 30 days HIV/AIDS Non-infectious Diarrhea FULYZAQ, MYTESI Documented diagnosis of HIV/AIDS in the past year AND Documented diagnosis of non- infectious diarrhea in the past year AND 1 claim for an antiretroviral in the past 30 days Short Bowel Syndrome (SBS) GATTEX, NUTRESTORE, ZORBTIVE 1 claim for the requested agent in the past 105 days OR

67

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

All new natients require clinical

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may n	not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.	

			 All new patients require clinical review Nutrestore Requires clinical review
LEUKOTRIENE MODIFIERS Sr	nartPA		
	kast granules kast tablets ist	ACCOLATE (zafirlukast) SINGULAIR Tablets (montelukast) SINGULAR GRANULES (montelukast granules) zileuton ZYFLO CR (zileuton)	 Minimum Age Limit 12 years – Zyflo & Zyflo CR Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months
LIPOTROPICS, OTHER (NON	I-STATINS) SmartPA		
	ACL INHIBITORS A	ND COMBINATIONS	
		NEXLETOL(bempedoic acid) NEXLIZET (bempedoic acid/ezetimibe)	Nexletol and NexlizetRequires clinical review
	BILE ACID SE	QUESTRANTS	
colestipo		colesevelam COLESTID (colestipol) QUESTRAN (cholestyramine) WELCHOL (colesevelam)	 All Agents, All Sub-Classes both Preferred (exception is Zetia) and Non-Preferred 90 consecutive days on the requested agent in the past 105 days OR Have tried 1 statin or statin combination agent in the past year OR One of the following exceptions: • Welchol AND Type 2 diabetes AND 1 preferred oral

68

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

OMEGA-3	S FATTY ACIDS	 antidiabetic agent in the past 180 days OR Pregnant female OR Documented diagnosis of liver disease OR Documented diagnosis for hypertriglyceridemia OR Clinical justification a statin or statin combination product cannot be used Non-Preferred Criteria Have tried 2 different preferred Non-statin Lipotropic agents in the past 6 months
omega 3 acid ethyl esters	LOVAZA (omega-3-acid ethyl esters)	Non-Preferred Criteria
	VASCEPA (icosapent ethyl)	Have tried 2 different preferred Non-statin Lipotropic agents in the past 6 months
CHOLESTEROL A	BSORPTION INHIBITORS	
ezetimibe	ZETIA (ezetimibe)	Zetia does not have to meet the trial of 1 statin or statin combination agent in the past year
FIBRIC AC	ID DERIVATIVES	
fenofibrate nanocrystallized gemfibrozil	ANTARA (fenofibrate, micronized) fenofibrate 40mg tablet fenofibrate, micronized fenofibric acid FENOGLIDE (fenofibrate) FIBRICOR (fenofibric acid) LIPOFEN (fenofibrate)	 Fibric Acid Derivative Non- Preferred Criteria Have tried 2 different fibric acid derivatives in the past 6 months

69

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



MISSISSIPPI DIVISION OF MEDICAID UNIVERSAL PREFERRED DRUG LIST

EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not					
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.					
		LOFIBRA (fenofibrate)			
		LOPID (gemfibrozil)			
		TRICOR (fenofibrate nanocrystallized)			
		TRIGLIDE (fenofibrate)			
		TRILIPIX (fenofibric acid)			
	MIPIN		Instantial MANUAL DA		
		JUXTAPID (lomitapide)	Juxtapid – <u>MANUAL PA</u>		
APOLIPOPROTEIN B-100 SYNTHESIS INHIBITOR					
		KYNAMRO (mipomersen)	Kynamro – <u>MANUAL PA</u>		
	NIA	ACIN			
	niacin ER NIACOR (niacin)	NIASPAN (niacin)	 Non-Preferred Criteria Have tried 2 different preferred Non-statin Lipotropic agents in the past 6 months 		
	PCSK-91	NHIBITOR			
		PRALUENT (alirocumab)	Praluent - MANUAL PA		
		REPATHA (evolocumab)	Repatha - MANUAL PA		
LIPOTROPICS, STATINS SmartPA					
STATINS					
	atorvastatin	ALTOPREV (lovastatin)	Simvastatin 80mg		
	lovastatin	CRESTOR (rosuvastatin)	• 12 months of therapy with		
	pravastatin	EZALLOR SPRINKLE (rosuvastatin)	simvastatin 80mg AND		
	rosuvastatin	FLOLIPID (simvastatin)	NO myopathy contraindication		

70

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

-nave electronic i A functional	lity. However, they must adhere to Medicaid's PA c		1		
	simvastatin	fluvastatin ER fluvastatin LESCOL (fluvastatin) LIPITOR (atorvastatin) LIVALO (pitavastatin) MEVACOR (lovastatin) PRAVACHOL (pravastatin) ZOCOR (simvastatin) ZYPITAMAG (pitavastatin)	 Non-Preferred Criteria Have tried 2 different preferred statin or statin combination agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days 		
	ezetimibe/simvastatin SIMCOR (simvastatin/niacin)	ADVICOR (lovastatin/niacin) atorvastatin/amlodipine CADUET (atorvastatin/amlodipine) LIPTRUZET (atorvastatin/ezetimibe) VYTORIN (simvastatin/ezetimibe)	 Non-Preferred Criteria Have tried 2 different preferred statin or statin combination agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days 		
MISCELLANEOUS BRAN	D/GENERIC				
		NIDINE			
	clonidine patches clonidine tablets EPINE	CATAPRES (clonidine) CATAPRES-TTS (clonidine) PHRINE			
	epinephrine autoinject pens (labeler 49502) SYMJEPI (epinephrine)	ADRENACLICK (epinephrine) AUVI-Q (epinephrine) EPINEPHRINE SNAP EMS KIT (epinephrine) EPIPEN (epinephrine) EPIPEN JR (epinephrine)	Quantity Limit • 2 kits/31 days		
MISCELLANEOUS					

71

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

	Application (SmartPA) is a proprietary electronic pri- lity. However, they must adhere to Medicaid's PA c	or authorization system used for Medicaid fee for ser	vice claims. MSCAN plans may/may not		
	alprazolam hydroxyzine hcl syrup hydroxyzine pamoate MAKENA (hydroxyprogesterone caproate) megestrol suspension 625mg/5mL	alprazolam ER hydroxyprogesterone caproate hydroxyzine hcl tablets KORLYM (mifepristone) MEGACE ES (megestrol) VISTARIL (hydroxyzine pamoate)	Alprazolam ER CUMULATIVE quantity limit • 31 tablets/31 days <u>Hydroxyzine HCI 10mg tablets</u> • 6-12 years - <u>Smart PA will</u> <u>automatically be issued for this age</u> <u>range</u>		
	ALLERGEN EXTRA	CT IMMUNOTHERAPY			
		GRASTEK ORALAIR <mark>PALFORZIA</mark> RAGWITEK			
	nitroglycerin lingual 12gm nitroglycerin sublingual NITROLINGUAL PUMPSPRAY (nitroglycerin) 12gm NITROSTAT SUBLINGUAL (nitroglycerin)	nitroglycerin lingual 4.9gm NITROLINGUAL (nitroglycerin) 4.9gm NITROMIST (nitroglycerin)			
MOVEMENT DISORDER AGENTS SmartPA					
	INGREZZA (valbenazine) tetrabenazine	AUSTEDO (deutetrabenazine) XENAZINE (tetrabenazine)	Ingrezza – <u>MANUAL PA</u> tetrabenazine: • Documented diagnosis of Huntington's Chorea Non-Preferred Criteria Austedo: • <u>MANUAL PA</u> for diagnosis of tardive dyskinesia O R		

72

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

· Documented diagnosis of Huntington's Chorea AND 30 days of therapy with preferred tetrabenazine in the past 6 months MULTIPLE SCLEROSIS AGENTS SmartPA AUBAGIO (teriflunomide) **All Agents** AMPYRA (dalfampridine) COPAXONE 40mg (glatiramer) Documented diagnosis of multiple AVONEX (interferon beta-1a) sclerosis AVONEX PEN (interferon beta-1a) dimethyl fumarate BETASERON (interferon beta-1b) EXTAVIA (interferon beta-1b) **Non-Preferred Criteria** COPAXONE 20mg (glatiramer) glatiramer Have tried 2 different preferred dalfampridine GLATOPA (glatiramer) agents in the past 6 months OR GILENYA (fingolimod) MAVENCLAD (cladribine) 3 claims with the requested agent MAYZENT (siponimod) REBIF (interferon beta-1a) in the last 105 days **REBIF REBIDOSE** (interferon beta-1a) OCREVUS (ocrelizumab) PLEGRIDY (interferon beta-1a) Kesimpta **TECFIDERA** (dimethyl fumarate) Requires clinical review VUMERITY (diroximel fumarate) Mavenclad – MANUAL PA ZINBRYTA (daclizumab) Mayzent – MANUAL PA **Ocrevus – MANUAL PA** MUSCULAR DYSTROPHY AGENTS EMFLAZA (deflazacort) Emflaza – MANUAL PA EXONDYS 51 (eteplirsen) Exondys – MANUAL PA VYONDYS 53 (golodirsen) Vyondys – MANUAL PA NSAIDS SmartPA NON-SELECTIVE

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	diclofenac EC diclofenac IR diclofenac SR etodolac IR tab flurbiprofen ibuprofen suspension ^{OTC} indomethacin ketoprofen ketorolac nabumetone naproxen 250mg and 500mg naproxen suspension piroxicam sulindac	ADVIL (ibuprofen) ANAPROX (naproxen) CAMBIA (diclofenac) CATAFLAM (diclofenac) DAYPRO (oxaprozin) etodolac cap etodolac tab SR FELDENE (piroxicam) FENORTHO (fenoprofen) fenoprofen INDOCIN capsules, suspension & suppositories (indomethacin) indomethacin cap ER ketoprofen ER meclofenamate mefenamic acid NALFON (fenoprofen) NAPRELAN (naproxen) NAPROSYN (naproxen) naproxen 275mg and 550mg NUPRIN (ibuprofen) oxaprozin PONSTEL (mefenamic acid) PROFENO (fenoprofen) RELAFEN DS (nabumetone) SPRIX NASAL SPRAY (ketorolac) TIVORBEX (indomethacin) tolmetin VOLTAREN XR (diclofenac) ZIPSOR (diclofenac)	Non-Preferred Criteria • Have tried 2 different preferred non- selective or NSAID/GI protectant combination agents in the past 6 months
--	--	--	---

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

NSAID	D/GI PROTECTANT COMBINATIONS ARTHROTEC (diclofenac/misoprostol) diclofenac/misoprostol DUEXIS (ibuprofen/famotidine) VIMOVO (naproxen/esomeprazole)	 Non-Preferred Criteria Have tried 2 different preferred non-selective or NSAID/GI protectant combination agents in the past 6 months
meloxicam	COX II SELECTIVE CELEBREX (celecoxib) celecoxib MOBIC (meloxicam) NULOX (meloxicam) QMIIZ ODT (meloxicam) VIVLODEX (meloxicam)	 Non-Preferred Criteria – COX II Documented diagnosis of Osteoarthritis, Rheumatoid Arthritis, Familial Adenomatous Polyposis, or Ankylosing Spondylitis AND 90 consecutive days on the requested agent in the past 105 days OR Have tried 1 preferred COX-II Selective and 1 preferred Non- Selective Agent OR Have tried 1 preferred COX-II Selective agent and a documented diagnosis of GI Bleed, GERD, PUD, GI Perforation, or Coagulation Disorder
OPHTHALMIC ANTIBIOTICS bacitracin/neomycin/gramicidin bacitracin/polymyxin ciprofloxacin erythromycin	AZASITE (azithromycin) bacitracin BESIVANCE (besifloxacin) BLEPH-10 (sulfacetamide)	

75

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

-nave electronic r A functional	inty. Thowever, they must adhere to Medicald STA of	111011a.
	GENTAK Ointment (gentamicin)	CILOXAN Ointment (ciprofloxacin)
	gentamicin	CILOXAN Solution (ciprofloxacin)
	ILOTYCIN (erythromycin)	GARAMYCIN (gentamicin)
	moxifloxacin	gatifloxacin
	ofloxacin	levofloxacin
	polymyxin/trimethoprim	MOXEZA (moxifloxacin)
	tobramycin	NATACYN (natamycin)
		neomycin/bacitracin/polymyxin b
		NEO-POLYCIN (neomy/baci/polymyxin b)
		NEOSPORIN (bacitracin/neomycin/gramicidin)
		(oxy-tcn/polymyx sul)
		OCUFLOX (ofloxacin)
		POLYTRIM (polymyxin/trimethoprim)
		sulfacetamide
		TOBREX drops (tobramycin)
		TOBREX ointment (tobramycin)
		VIGAMOX (moxifloxacin)
		ZYMAR (gatifloxacin)
		ZYMAXID (gatifloxacin)
	ANTIBIOTIC STER	DID COMBINATIONS
	BLEPHAMIDE (sulfacetamide/prednisolone) drops,oint neomycin/bacitracin/polymyxin/hc ointment neomycin/polymyxin/dexamethasone PRED-G (gentamicin/prednisolone)drops, oint sulfacetamide/prednisolone TOBRADEX SUSPENSION/OINTMENT (tobramycin/dexamethasone) ZYLET (loteprednol/tobramycin)	gatifloxacin/prednisolone MAXITROL(neomycin/polymyxin/dexamethasone) neomycin/polymyxin/gramicidin neomycin/polymyxin/hydrocortisone TOBRADEX ST SUSPENSION (tobramycin/dexamethasone) tobramycin/dexamethasone

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

OPHTHALMIC AN	TI-INFLAMMATORIES SmartPA		
	dexamethasone diclofenac DUREZOL (difluprednate) FLAREX (fluorometholone) fluorometholone flurbiprofen FML FORTE (fluorometholone) FML SOP (fluorometholone) ketorolac loteprednol etabonate MAXIDEX (dexamethasone) prednisolone acetate prednisolone NA phosphate PRED MILD (prednisolone) VEXOL (rimexolone)	ACULAR (ketorolac) ACULAR LS (ketorolac) ACUVAIL (ketorolac) BROMDAY (bromfenac) bromfenac BROMSITE (bromfenac) FML (fluorometholone) ILEVRO (nepafenac) INVELTYS (loteprednol etabonate) LOTEMAX (loteprednol) LOTEMAX (loteprednol) OCUFEN (flurbiprofen) OMNIPRED (prednisolone) NEVANAC (nepafenac) PRED FORTE (prednisolone) PROLENSA (bromfenac) VOLTAREN (diclofenac)	 Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months
OPHTHALMICS F	OR ALLERGIC CONJUNCTIVITIS Sma	artPA	
	ALREX (loteprednol) azelastine cromolyn olopatadine 0.1% olopatadine 0.2%	ALOCRIL (nedocromil) ALOMIDE (lodoxamide) BEPREVE (bepotastine) epinastine LASTACAFT (alcaftadine) PATADAY (olopatadine) PATANOL (olopatadine) PAZEO (olopatadine) ZERVIATE (cetirizine)	 Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months
OPHTHALMIC, DF	RY EYE AGENTS		
	RESTASIS droperette (cyclosporine)	CEQUA (cyclosporine 0.09%)	Minimum Age Limit

77

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	COMBINATION AGENTS	
	TRUSOPT (dorzolamide)	
dorzolamide	AZOPT (brinzolamide)	
	ONIC ANHYDRASE INHIBITORS	
	TIMOPTIC XE (timolol)	
timolol drops 0.25%, 0.5%	TIMOPTIC (timolol)	-
metipranolol	timolol gel timolol daily drop 0.5% (generic Istalol)	days
levobunolol	OPTIPRANOLOL (metipranolol)	 90 consecutive days on the requested agent in the past 105
ISTALOL (timolol)	BETOPTIC S (betaxolol)	agents in the past 6 months OR
carteolol	betaxolol	Have tried 2 different preferred
BETIMOL (timolol)	BETAGAN (levobunolol)	Non-Preferred Criteria
	BETA BLOCKERS	
OPHTHALMIC, GLAUCOMA AGENTS SmartPA		
		the past 6 months
		History of 4 claims for Restasis in
		Non-Preferred Criteria:
		droperette, Xiidra
		• 60 units/31 days – Cequa, Restasis
		Multidose
		Quantity Limit • 5.5 mL/31 days – Restasis
	XIDIV (Integrate)	• 18 years – Cequa
	RESTASIS Multidose (cyclosporine) XIIDRA (lifitegrast) ^{Smart PA}	 16 years – Restasis 17 years – Xiidra

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

nuve electronic 111 functiona	inty. Thowever, they must adhere to Medicald STAC	interna.	
	COMBIGAN (brimonidine/timolol) dorzolamide/timolol	COSOPT (dorzolamide/timolol) COSOPT PF(dorzolamide/timolol) SIMBRINZA (brinzolamide/brimonidine)	
	PARASYMPA	THOMIMETICS	
	pilocarpine	CARBOPTIC (carbachol) ISOPTO CARBACHOL (carbachol) ISOPTO CARPINE (pilocarpine) PHOSPHOLINE IODIDE (echothiophate iodide) PILOPINE HS (pilocarpine)	
	PROSTAGLAM	NDIN ANALOGS	
	latanoprost	bimatoprost LUMIGAN (bimatoprost) TRAVATAN Z (travoprost) travoprost XALATAN (latanoprost) XELPROS (lantanoprost) VYZULTA (latananoprostene bunod) ZIOPTAN (tafluprost)	
	RHO KINASE INHIBI	TORS/COMBINATIONS	
	RHOPRESSA (netarsudil) ROCKLATAN (netarsudil/latanoprost) SYMPATH	OMIMETICS	
	brimonidine 0.2%	ALPHAGAN P 0.1% (brimonidine) ALPHAGAN P 0.15% (brimonidine) brimonidine 0.15% dipivefrin PROPINE (dipivefrin)	

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

OPIATE DEPENDENCE TREATMENTS

OFIATE DEFENDENCE			
	DEPEN	DENCE	
	buprenorphine/naloxone film labeler 52427 buprenorphine/naloxone tablets naltrexone tablets SUBOXONE FILM (buprenorphine/naloxone) ^{SmartPA}	buprenorphine tablets BUNAVAIL (buprenorphine/naloxone) buprenorphine/naloxone films all other labelers LUCEMYRA (lofexidine) PROBUPHINE (buprenorphine) SUBLOCADE (buprenorphine) VIVITROL (naltrexone) ZUBSOLV (buprenorphine/naloxone)	 Buprenorphine/Naloxone and buprenorphine: Non-Preferred Criteria: Bunavail is preferred over Zubsolv and other generic forms of buprenorphine/naloxone Bunavail NOTE: Bunavail is not indicated for induction therapy History of Suboxone therapy within the past 6 months OR History of Bunavail therapy within the past 3 months AND All other buprenorphine/naloxone provider summary found here Probuphine – MANUAL PA Sublocade – MANUAL PA Vivitrol - MANUAL PA
	TREA	IMENT	
	naloxone injection NARCAN NASAL SPRAY (naloxone)	EVZIO (naloxone)	
OTIC ANTIBIOTICS			
	CIPRODEX (ciprofloxacin/dexamethasone) CIPRO HC (ciprofloxacin/hydrocortisone) Age Edit ofloxacin	ciprofloxacin ciprofloxacin/dexamethasone ciprofloxacin/fluocinolone	Maximum Age Limit • 9 years - Cipro HC

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

	Application (SmartPA) is a proprietary electronic pri lity. However, they must adhere to Medicaid's PA c	or authorization system used for Medicaid fee for serv riteria.	vice claims. MSCAN plans may/may not
		CORTISPORIN-TC (colistin/neomycin/ hydrocortisone) DERMOTIC (fluocinolone) FLAC OIL DROP (fluocinolone oil) hydrocortisone/acetic acid drop fluocinolone oil neomycin/polymyxin/hydrocortisone OTIPRIO (ciprofloxacin) OTOVEL (ciprofloxacin/fluocinolone)	
PANCREATIC ENZYMI	ES SmartPA		
	CREON (pancreatin) ZENPEP (pancrelipase)	PANCREAZE (pancrelipase) PERTZYE (pancrelipase) VIOKACE (pancrelipase)	 Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months
PARATHYROID AGEN	TS		
	calcitriol ergocalciferol paricalcitol ROCALTROL (calcitriol) ZEMPLAR (paricalcitol)	cinacalcet doxercalciferol DRISDOL (ergocalciferol) HECTOROL (doxercalciferol) NATPARA (parathyroid hormone) RAYALDEE (calcifediol) SENSIPAR (cinacalcet)	
PHOSPHATE BINDERS	8		
	calcium acetate ELIPHOS (calcium acetate) PHOSLYRA (calcium acetate) sevelamer carbonate tablets	AURYXIA (ferric citrate) FOSRENOL (lanthanum) lanthanum PHOSLO (calcium acetate) RENAGEL (sevelamer HCI) RENVELA (sevelamer carbonate) sevelamer carbonate powder packets	

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

-have electronic PA	Pharmacy Application (SmartPA) is a proprietary electron A functionality. However, they must adhere to Medicaid's	PA criteria. sevelamer HCI VELPHORO (sucroferric oxyhydronxide)	
PLATELET AG	GREGATION INHIBITORS SmartPA		
	AGGRENOX (dipyridamole/aspirin) BRILINTA (ticagrelor) cilostazol clopidogrel dipyridamole dipyridamole/aspirin labeler 70436 pentoxifylline prasugrel	dipyridamole/aspirin all other labelers DURLAZA ER (aspirin) EFFIENT (prasugrel) omeprazole/asprin PERSANTINE (dipyridamole) PLAVIX (clopidogrel) PLETAL (cilostazol) ticlopidine YOSPRALA (aspirin/omeprazole) ZONTIVITY (vorapaxar)	 Zontivity – <u>MANUAL PA</u> Non-Preferred Criteria Documented diagnosis AND Have tried 2 different preferred agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
PLATELET ST	IMULATING AGENTS		
	PROMACTA (eltrombopag olamine)	DOPTELET (avatrombopag maleate) MULPLETA (lusutrombopag) NPLATE (romiplostim) TAVALISSE (fostamatinib disodium)	
PRENATAL VI	TAMINS		
	COMPLETE NATAL DHA CONCEPT DHA Capsule PRENATA CHEWABLE Tablet PRENATAL PLUS Tablet PRENATAL VITAMIN PLUS LOW IRON Tabl PREPLUS Ca/Fe27/FA 1 Tablet TARON-C DHA Capsule TRICARE PRENATAL Tablet TRINATAL Rx 1 Tablet	Products not listed here are assumed to be Nor Preferred.	n-

82

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

•	Application (SmartPA) is a proprietary electronic pality. However, they must adhere to Medicaid's PA TRIVEEN-DUO DHA COMBO PACK		service claims. MSCAN plans may/may not
PSEUDOBULBAR AF	FECT AGENTS		
		NUEDEXTA (dextromethorphan/quinidine)	 Non-Preferred Criteria 90 consecutive days on the requested agent in the past 105 days OR Documented diagnosis for Pseudobulbar Affect
PULMONARY ANTIHY	(PERTENSIVES ^{SmartPA}		
	ENDOTHELIN REC	CEPTOR ANTAGONIST	
	ambrisentan TRACLEER (bosentan) Tablets	bosentan LETAIRIS (ambrisentan)* OPSUMIT (macitentan) TRACLEER (bosentan) Suspension	 All PAH Agents Documented diagnosis of pulmonary hypertension Non-Preferred Criteria Have tried 1 preferred PAH agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
	P	DE5's	
	sildenafil (generic Revatio) tablet tadalafil	ADCIRCA (tadalafil) REVATIO (sildenafil) tablet REVATIO (sildenafil) suspension sildenafil (generic Revatio) suspension	 Non-Preferred Criteria Have tried 1 preferred PAH agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days Revatio suspension

83

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		 < 12 years of age AND Documented diagnosis of Pulmonary Hypertension, Patent Ductus Arteriosus, or Persistent Fetal Circulation or history of heart transplant OR 90 consecutive days on the requested agent in the past 105 days < 1 year of age AND Documented diagnosis of Pulmonary Hypertension, Patent Ductus Arteriosus, or Persistent Fetal Circulation OR 90 consecutive days on the requested agent in the past 105 days OR > 1 years of age AND Have tried 1 preferred PAH agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days OR
PROSTA	CYCLINS	
	ORENITRAM ER (treprostinil) TYVASO (treprostinil) VENTAVIS (iloprost)	 Non-Preferred Criteria Have tried 1 preferred PAH agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days

84

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

SELECTIVE PRO	STACYCLIN RECEPTOR AGONISTS	
	UPTRAVI (selexipag)	 Non-Preferred Criteria Have tried 1 preferred PAH agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days
SOLUABLE GUA	NYLATE CYCLASE STIMULATORS	
	ADEMPAS (riociguat)	 Adempas Have tried 1 preferred PAH agent in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days OR Clinical review required for PAH WHO Group 4
ROSACEA TREATMENTS		
metronidazole (cream, gel, lotion)	AVAR (sulfacetamide sodium/sulfur) FINACEA (azelaic acid) METROCREAM (metronidazole cream) METROGEL (metronidazole gel) METROLOTION (metronidazole lotion) MIRVASO (brimonidine) NORITATE (metronidazole) OVACE (sulfacetamide sodium) RHOFADE (oxymetazoline HCI) ROSULA (sodium sulfacetamide/sulfur)	Topical Sulfonamides used for Rosacea will require a manual PA for ≥21 years. Other labeled indications are limited to <21 years.

85

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		sodium sulfacetamide/sulfur (cleanser, pads, suspension) SOOLANTRA (ivermectin) SUMADAN(sodium sulfacetamide/sulfur wash) SUMAXIN(sodium sulfacetamide/sulfur pads) SUMAXIN TS(sodium sulfacetamide/sulfur suspension)	
SEDATIVE HYPNOTICS			
	BENZODIAZE	PINES SmartPA	
	estazolam flurazepam temazepam (15mg and 30mg)	DALMANE (flurazepam) DAYVIGO (lemborexant) DORAL (quazepam) HALCION (triazolam) quazepam RESTORIL (temazepam) temazepam (7.5mg and 22.5mg) triazolam	Single source benzodiazepines and barbiturates are NOT covered – NO PA's will be issued for these drugs. MS DOM Opioid Initiative • Concomitant use of Opioids and Benzodiazepines <u>Criteria details found here</u> Quantity Limit – CUMULATIVE Quantity limit per rolling days for all strengths. <i>SmartPA will allow an early</i> <i>refill override for one dose or therapy</i> <i>change per year.</i> • 31 units/31 days - all strengths Triazolam – CUMULATIVE Quantity limit per rolling days for all strengths • 10 units/31 days • 60 units/365 days
	OTHERS	S SmartPA	

86

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



SE

MISSISSIPPI DIVISION OF MEDICAID UNIVERSAL PREFERRED DRUG LIST

EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

	zalepion zolpidem	AMBIEN (zolpidem) AMBIEN CR (zolpidem) BELSOMRA (sovorexant) doxepin EDLUAR (zolpidem) eszopiclone HETLIOZ (tasimelteon) INTERMEZZO (zolpidem) LUNESTA (eszopiclone) ramelteon ROZEREM (ramelteon) SILENOR (doxepin) SONATA (zaleplon) zolpidem ER zolpidem SL ZOLPIMIST (zolpidem)	 Quantity Limit – CUMULATIVE Quantity limit per rolling days for all strengths. SmartPA will allow an early refill override for one dose or therapy change per year. 31 units/31 days 1 canister/31 days – Zolpimist & male 1 canister/62 days – Zolpimist & female Gender and Dose Limit for zolpidem Female – Ambien 5mg, Ambien CR 6.25mg, Intermezzo 1.75 mg Male – all zolpidem strengths Non-Preferred Criteria Have tried 2 different preferred agents in the past 6 months Hetlioz Circadian rhythm sleep disorder AND Diagnosis indicating total blindness of the patient
ELECT CONTRACEP			
		ONTRACEPTIVES	
	medroxyprogesterone acetate IM	DEPO-PROVERA IM (medroxyprogesterone acetate) DEPO-SUBQ PROVERA 104 (medroxyprogesterone acetate)	

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

INTRAVAGINAL	CONTRACEPTIVES	
ANNOVERA (segesterone/ethinyl estradiol) etonogestrel/ethinyl estradiol NUVARING (etonogestrel/ethinyl estradiol)		
ORAL CONTRAC	CEPTIVES SmartPA	
ALL CONTRACEPTIVES ARE PREFERRED EXCEPT FOR THOSE SPECIFICALLY INDICATED AS NON-PREFERRED	AMETHIA (levonorgestrel/ethinyl estradiol) AMETHYST (levonorgestrel/ethinyl estradiol) AUROVELA 24FE (norethindrone/ethinyl estradiol/iron) BEYAZ (ethinyl estradiol / drospirenone/levomefolate) BLISOVI 24FE (norethindrone/ethinyl estradiol/iron) BRIELLYN (norethindrone/ethinyl estradiol) CAMRESE (levonorgestrel/ethinyl estradiol) CAMRESE LO (levonorgestrel/ethinyl estradiol) ethinyl estradiol/drospirenone GENERESS FE (norethindrone/ethinyl estradiol/fe) GIANVI (ethinyl estradiol/drospirenone) HAILEY 24 FE (norethindrone/ethinylestradiol/iron) JOLESSA (levonorgestrel/ethinyl estradiol) JUNEL 24 FE (norethindrone/ethinylestradiol/iron) LARIN 24 FE (norethindrone/ethinylestradiol/iron) LARIN 24 FE (norethindrone/ethinylestradiol/iron) LOESTRIN FE (norethindrone/ethinylestradiol/iron) LOVIS FE (norethindrone/ethinylestradiol/iron) LORYNA (ethinyl estradiol/drospirenone) LO-ZUMANDIMINE (ethinyl estradiol/drospirenone)	Non-Preferred Criteria • 1 claim with the requested agent in the past 105 days

88

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary elec- have electronic PA functionality. However, they must adhere to Medica	1 V	service claims. MSCAN plans may/may not
	NATAZIA (estradiol valerate/dienogest) norethindrone/ethinyl estradiol/fe chew tab OCELLA (ethinyl estradiol/drospirenone) PHILITH (norethindrone/ethinyl estradiol) SAFYRAL (ethinyl estradiol/ drospirenone/levomefolate) SIMPESSE (levonorgestrel/ethinyl estradiol) SYEDA (ethinyl estradiol/drospirenone) TARNIA (norethindrone/ethinyl estradiol/iron) WYMZYA FE (norethindrone/ethinyl estradiol/fe) ZARAH (ethinyl estradiol/drospirenone) ZUMANDIMINE (ethinyl estradiol/drospirenone)	
SICKLE CELL AGENTS		
<mark>DROXIA (hydroxyurea)</mark> hydroxyurea	ADAKVEO (crizanlizumab) ENDARI (glutamine) HYDREA (hydroxyurea) OXBRYTA (voxelotor) SIKLOS (hydroxyurea	Endari – <u>MANUAL PA</u> Oxbryta – <u>MANUAL PA</u>
SKELETAL MUSCLE RELAXANTS SmartPA		
baclofen chlorzoxazone cyclobenzaprine 5mg, 10mg methocarbamol tizanidine tablets	AMRIX (cyclobenzaprine ER) carisoprodol carisoprodol compound cyclobenzaprine 7.5mg, 15mg cyclobenzaprine ER DANTRIUM (dantrolene) dantrolene FEXMID (cyclobenzaprine) FLEXERIL (cyclobenzaprine) LORZONE (chlorzoxazone)	 Non-Preferred Agents Documented diagnosis for an approvable indication AND Have tried 2 different preferred agents in the past 6 months Carisoprodol Documented diagnosis of acute musculoskeletal condition AND NO history with meprobamate in the past 90 days AND

89

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		metaxalone NORGESIC FORTE (orphenedrine) orphenadrine compound orphenadrine ER PARAFON FORTE DSC (chlorzoxazone) ROBAXIN (methocarbamol) SKELAXIN (metaxalone) SOMA (carisoprodol) tizanidine capsules ZANAFLEX (tizanidine)	 1 claim for cyclobenzaprine in the past 21 days OR a documented intolerance to cyclobenzaprine AND Quantity Limit 18 tablets - to allow tapering off 84 tablets/6 months Carisoprodol with codeine Requires clinical review
SMOKING DETERRENT			
	nicotine gum ^{OTC} nicotine lozenge ^{OTC} nicotine mini lozenge ^{OTC} nicotine patch ^{OTC}	NE TYPE NICODERM CQ PATCH ^{OTC} NICORETTE GUM ^{OTC} NICORETTE LOZENGE ^{OTC} NICORETTE MINI LOZENGE ^{OTC} NICOTROL INHALER CARTRIDGE NICOTROL NASAL SPRAY	
	NON-NICO	TINE TYPE	
	bupropion ER CHANTIX (varenicline)	ZYBAN (bupropion)	Minimum Age Limit - Chantix • 18 years Quantity Limit • Chantix 0.5 mg, 1mg tablets and continuing pack – 336 tablets/year • Chantix Starter – 2 treatment courses/year
STEROIDS (Topical) Sma	artPA		

90

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

LOW POTENCY				
	CAPEX (fluocinolone) desonide hydrocortisone cr, oint, soln.	alclometasone DERMA-SMOOTHE-FS (fluocinolone) DESONATE (desonide) DESOWEN (desonide) fluocinolone oil hydrocortisone lotion PEDIACARE HC (hydrocortisone) PEDIADERM (hydrocortisone) VERDESO (desonide)	 Non-Preferred Criteria Have tried 2 different preferred low potency agents in the past 6 months 	
	MEDIUM	I POTENCY		
	fluocinolone hydrocortisone mometasone cr, oint. prednicarbate cr PANDEL (hydrocortisone probutate)	betamethasone valerate foam CLODERM (clocortolone) CUTIVATE (fluticasone) DERMATOP (prednicarbate) ELOCON (mometasone) fluticasone LUXIQ (betamethasone) mometasone solution MOMEXIN (mometasone) prednicarbate oint SYNALAR (fluocinolone)	 Non-Preferred Criteria Have tried 2 different preferred medium potency agents in the past 6 months 	
	HIGH I	POTENCY		
	amcinonide cr, lot betamethasone dipropionate cr, gel, lotion betamethasone valerate cr, lotion, oint. fluocinolone triamcinolone	amcinonide oint betameth diprop/prop gly cr, lot, oint betamethasone dipropionate oint. BETA-VAL (betamethasone valerate) desoximetasone diflorasone DIPROLENE AF (betamethasone diprop/prop gly) ELOCON (mometasone)	 Non-Preferred Criteria Have tried 2 different preferred high potency agents in the past 6 months 	

91

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.			
	fluocinonide HALOG (halcinonide) KENALOG (triamcinolone)		
	PEDIADERM TA (triamcinolone) SERNIVO (betamethasone dipropionate) TOPICORT (desoximetasone)		
	TRIANEX (triamcinolone) VANOS (fluocinonide)		
	VERY HIGH POTENCY		
clobetasol lotion clobetasol shampoo, spra clobetasol propionate crea clobetasol propionate oint halobetasol cream halobetasol ointment	am clobetasol propionate foam, ge	 Non-Preferred Criteria Have tried 2 different preferred very high potency agents in the past 6 months 	

STIMULANTS AND RELATED AGENTS SmartPA

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.
PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.

To search the PDL, press CTRL + F



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

SHORT-ACTING				
amphetamine salt combination dexmethylphenidate IR methylphenidate solution PROCENTRA (dextroamphetamine)	ADDERALL (amphetamine salt combination) Amphetamine sulfate (generic EVEKO) DESOXYN (methamphetamine) dextroamphetamine solution EVEKEO (amphetamine) EVEKEO ODT(amphetamine) FOCALIN (dexmethylphenidate) methamphetamine METHYLIN solution (methylphenidate) methylphenidate chewable RITALIN (methylphenidate) ZENZEDI (dextroamphetamine)	 Minimum Age Limit 3 years - Adderall, Evekeo, Procentra, Zenzedi 6 years - Desoxyn, Evekeo ODT, Focalin, Methylin Maximum Age Limit 18 years - Evekeo ODT Quantity Limit Applicable <u>quantity limit</u> per rolling days 62 tablets/31 days - Adderall, Desoxyn, Evekeo, Focalin, Methylin, Zenzedi 310 mL/31 days - Methylin solution, Procentra Documented diagnosis of ADHD - ALL Short Acting AGENTS Non-Preferred Criteria ADD/ADHD: Documented diagnosis of ADD/DHD AND Have tried 2 different preferred Short Acting agents in the past 6 months OR 1 claim for a 30 day supply with the requested agent in the past 105 days 		

93

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

METHYLIN, PROCENTRA, RITALIN,

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		ZENZEDI
LONG-	ACTING	
amphetamine salt combination ER APTENSIO XR (methylphenidate) FOCALIN XR (dexmethylphenidate) methylphenidate CD (generic Metadate CD) methylphenidate ER (generic Concerta) methylphenidate ER Tabs (generic Ritalin SR) QUILLICHEW (methylphenidate) QUILLIVANT XR (methylphenidate) VYVANSE (lisdexamfetamine) VYVANSE (lisdexamfetamine) VYVANSE CHEWABLE (lisdexamfetamine)	ADDERALL XR (amphetamine salt combination) ADHANSIA XR (methylphenidate) ADZENYS XR ODT (amphetamine) ADZENYS ER SUSPENSION (amphetamine) CONCERTA (methylphenidate) COTEMPLA XR-ODT (methylphenidate) DAYTRANA (methylphenidate) DEXEDRINE (dextroamphetamine) dexmethylphenidate ER dextroamphetamine ER DYNAVEL XR (amphetamine) JORNAY PM (methylphenidate) methylphenidate ER caps (generic Aptensio XR) methylphenidate ER caps (generic Ritalin LA) methylphenidate ER (generic Relexxi) MYDAYIS (amphetamine salt combination) RELEXXI (methylphenidate) RITALIN LA (methylphenidate) RITALIN SR (methylphenidate)	 Minimum Age Limit 6 years – Adderall XR, Adhansia XR, Adzenys ER Suspension, Adzenys XR ODT, Aptensio XR, Concerta, Cotempla XR ODT, Daytrana, Dexedrine, Dynavel XR Focalin XR, Jornay PM, Metadate, CD, methylphenidate ER 72mg, Quillichew, Quillivant XR, Ritalin LA, Vyvanse 13 years – Mydayis 16 years – Provigil 18 years – Nuvigil, Sunosi Maximum Age Limit 18 years – Cotempla XR ODT, Daytrana Quantity Limit Applicable <u>quantity limi</u>t per rolling days 31 tablets/31 days – Adderall XR, Adhansia XR, Adzenys XR ODT, Aptensio XR, Concerta 18, 27, & 54 mg, Cotempla XR-ODT 8.6 mg, Daytrana, Dexedrine Spansule, Focalin XR, Jornay PM, Metadate CD, Methylin ER, methylphenidate

94

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			ER 72mg, Nuvigil 150, 200 & 250 mg, Provigil 200mg, Quillichew, Ritalin LA & SR, Vyvanse, Sunosi • 46.5 tablets/31 days – Provigil 100 mg • 62 tablets/31 days – Concerta 36mg, Cotempla XR-ODT 17.3 & 25.9 mg, Nuvigil 50mg • 248 mL/31 days – Dynavel XR • 372 mL/31 days – Quillivant XR Documented diagnosis of ADHD – ALL Long Acting AGENTS Documented diagnosis of binge eating disorder – VYVANSE Non-Preferred Criteria ADD/ADHD: • Documented diagnosis of ADD/ADHD AND • Have tried 2 different preferred Long Acting agents in the past 6 months OR • 1 claim for a 30 day supply with the requested agent in the past 105 days
	NARCO	LEPSY	
armodafinil modafinil		NUVIGIL (armodafinil) PROVIGIL (modafinil) SUNOSI (solriamfetol) WAKIX (pitolisant) XYREM (sodium oxybate)	Documented diagnosis of narcolepsy – ADDERALL XR, APTENSIO XR, CONCERTA ER, DEXEDRINE, METADATE CD, METHYLIN ER, MYDAYIS, NUVIGIL, PROVIGIL,QUILLICHEW,

95

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit. Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

QUILLIVANT XR, RITALIN LA, SUNOSI

Non-Preferred Criteria narcolepsy:

- Documented diagnosis of narcolepsy AND
- 30 days of therapy with preferred modafinil or armodafinil in the past 6 months **AND**
- 1 different preferred Long Acting agent indicated for narcolepsy in the past 6 months **OR**
- 1 claim for a 30 day supply with the
- requested agent in the past 105 days

Nuvigil

 Documented diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder or bipolar depression

Provigil

 Documented diagnosis of narcolepsy, obstructive sleep apnea, shift work sleep disorder, depression, sleep deprivation or Steinert Myotonic Dystrophy Syndrome

Sunosi

96

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

- Decumented diagnosis of

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		 Documented diagnosis of narcolepsy or obstructive sleep apnea AND 30 days of therapy with preferred modafinil or armodafinil in the past 6 months
		 Wakix Diagnosis of narcolepsy without cataplexy AND 30 days of therapy with preferred modafinil or armodafinil in the past 6 months OR Documented diagnosis of narcolepsy without cataplexy or substance abuse disorder Xyrem and Xywav Requires clinical review
NON-ST	MULANTS	
atomoxetine guanfacine ER ^{Step Edit}	clonidine ER INTUNIV (guanfacine ER) KAPVAY (clonidine extended-release) STRATTERA (atomoxetine)	 Minimum Age Limit 6 years – Intuniv, Kapvay, Strattera 18 years – Wakix Maximum Age Limit 18 years – Intuniv, Kapvay 21 years – diagnosis of ADD/ADHD is required for Strattera Quantity Limit Applicable <u>quantity limit</u> per rolling days 31 tablets/31 days – Intuniv, Strattera

97

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			 62 tablets/31days - Wakix 124 tablets/31 days – Kapvay 		
			 Intuniv Have tried the short acting guanfacine in the past 6 months OR 1 claim for a 30 day supply with guanfacine ER in the past 105 days 		
			 Kapvay Diagnosis for ADD or ADHD AND Have tried 1 Short or Long Acting stimulant in the past 6 months OR Have tried 1 preferred Non-Stimulant in the past 6 months OR Have tried the short acting product in the past 6 months 		
TETRACYCLINES SmartPA					
	doxycycline hyclate caps/tabs doxycycline monohydrate caps (50mg & 100mg) minocycline caps IR tetracycline	ACTICLATE (doxycyline) ADOXA (doxycycline monohydrate) demeclocycline doxycycline hyclate (generic Doryx) doxycycline monohydrate caps (75mg & 150mg) doxycycline monohydrate tabs DORYX (doxycycline hyclate) DYNACIN (minocycline) MINOCIN (minocycline) MINOLIRA (minocycline)	 Non-Preferred Agents Have tried 2 different preferred agents in the past 6 months Demeclocycline Documented diagnosis of Diabetes Insipidus or SIADH will allow automatic approval. 		

98

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



U

MISSISSIPPI DIVISION OF MEDICAID UNIVERSAL PREFERRED DRUG LIST

EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not
-have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

		minocycline ER minocycline tabs MONODOX (doxycycline monohydrate) NUZYRA (omadacycline tosylate) OKEBO (doxycycline) ORACEA (doxycycline) SEYSARA (sarecycline) SOLODYN (minocycline) TARGADOX (doxycycline) VIBRAMYCIN cap/susp/syrup XIMINO (minocycline)				
ULCERATIVE COLITIS and CROHN'S AGENTS SmartPA *See Cytokine & CAM Antagonists Class for additional agents						
	OF	RAL				
	balsalazide mesalamine tablet (generic Apriso) sulfasalazine	APRISO (mesalamine) ASACOL HD (mesalamine) AZULFIDINE (sulfasalazine) AZULFIDINE ER (sulfasalazine) budesonide EC COLAZAL (balsalazide) DELZICOL (mesalamine) DIPENTUM (olsalazine) ENTOCORT EC (budesonide) GIAZO (balsalazide) LIALDA (mesalamine) mesalamine tablet (generic Asacol HD) mesalamine tablet (generic Delzicol) PENTASA 250mg (mesalamine) PENTASA 500mg (mesalamine) UCERIS (budesonide)	 Gender Limit Male - Giazo Non-Preferred Criteria Documented diagnosis for Ulcerative Colitis AND 2 different preferred agents in the past 6 months OR 90 consecutive days on the requested agent in the past 105 days budesonide EC Documented diagnosis for Crohn's disease OR Documented diagnosis for Ulcerative Colitis AND 2 different preferred agents in the past 6 months OR 			

99

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories.

Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.



EFFECTIVE 10/01/2020 Version 2020.6 Updated: 11-24-2020

(For All Medicaid, MSCAN and CHIP Beneficiaries)

Conduent's SmartPA Pharmacy Application (SmartPA) is a proprietary electronic prior authorization system used for Medicaid fee for service claims. MSCAN plans may/may not -have electronic PA functionality. However, they must adhere to Medicaid's PA criteria.

			 90 consecutive days on the requested agent in the past 105 days
RECTAL			
	mesalamine suppository	CANASA (mesalamine) ROWASA (mesalamine) SF-ROWASA (mesalamine) UCERIS Foam (budesonide)	

100

Drug coverage subject to the rules and regulations set forth in Sec. 1927 of Social Security Act. This is not an all-inclusive list of available covered drugs and includes only managed categories. Unless otherwise stated, the listing of a particular brand or generic name includes all dosage forms of that drug. NR indicates a new drug that has not yet been reviewed by the P&T Committee.

PREFERRED BRANDS will not count toward the two brand monthly Rx limit.

Drugs highlighted in yellow denote a change in PDL status.

An * denotes existing users will be grandfathered; grandfathering is defined as approving a Non-Preferred agent for an existing user; all other changes will not qualify for grandfathering.

A # denotes existing users will NOT be grandfathered.